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Abstract 
 
DNA double strand breaks (DSBs) are primarily repaired in eukaryotic cells by two 
different mechanisms – non-homologous end joining (NHEJ) or homologous 
recombination (HR). In mammalian somatic cells the balance between the two highly 
favours NHEJ. Gene targeting is a technique that exploits HR repair to alter a defined 
gene locus. While it holds potential to be implemented as a treatment option for several 
diseases, the outlook for using it in a clinical setting has been obstructed by a low gene 
targeting efficiency. This has been coupled to the low frequency of HR in mammalian 
cells. With the intention of shifting the repair balance, antibodies against DSB repair 
proteins will be introduced into mammalian cells. It is predicted that by targeting key 
repair proteins with antibodies, a compensatory increase in the frequency of HR can be 
fostered, ultimately resulting in improved gene targeting.  
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Chapter 1: Introduction 
 
1.1 Introduction 
 
DNA double strand break (DSB) repair is an essential cellular process (Hartlerode & 
Scully, 2009; Ohnishi et al., 2009; Sonoda et al., 2006). Every day cells are subjected to 
exogenous and endogenous factors causing DSBs including but not limited to ionizing 
radiation (IR) (Banath, 2003), chemical reagents (Hammond et al., 2003), V(D)J 
recombination (Klein et al., 1996), and senescence (Sedelnikova et al., 2004). If these 
breaks remain unrepaired they can be very damaging to the cell and culminate in 
translocations, DNA loss, mutations, and eventually even apoptosis (Jackson & Bartek, 
2009; Ohnishi et al., 2009; Sonoda et al., 2006). There are two main competing pathways 
for repairing DNA DSBs in cells -- nonhomologous end joining (NHEJ) and homologous 
recombination (HR) (Helleday et al., 2007; Li & Heyer, 2008; Lieber, 2008). NHEJ 
involves the direct ligation of the DSB ends with little regard for homology, whereas in 
HR the broken strand is repaired using the homology of the strand’s sister chromatid or 
homologous chromosome counterpart (Ohnishi et al., 2009; Tamura et al., 2002). It has 
been proposed that some degree of direct competition between these two repair pathways 
may exist (Sonoda et al., 2006).  
 
In the past decade the manipulation of these DNA repair pathways has been investigated 
as a potential means to improve current gene targeting methods (de Boer et al., 2010; 
Fattah et al., 2008; Iiizumi et al., 2008; Pierce et al., 2001). Gene targeting is a type of 
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genetic engineering that utilizes the HR DNA repair pathway to replace a specific 
targeted gene loci within an organism’s genome (Fattah et al., 2008). This approach has 
often been applied when generating knockouts through the deletion of an entire gene. By 
observing the resulting phenotype when a specific gene is absent its function, importance, 
and corresponding gene products can be elucidated. More recently, however, it has 
become applicable to the medical field through the development and investigation of 
gene therapy (Akhtar et al., 2011; Bainbridge et al. 2006; Fattah et al., 2008). Gene 
therapy essentially involves the rectification of disease-causing mutations by exchanging 
a mutated copy of a gene sequence for its healthy, wild-type equivalent (Fattah et al., 
2008). 
 
The field of gene therapy began to take shape when DNA was finally revealed as the 
driving force behind heredity, gene expression, and ultimately phenotype (Avery et al., 
1944). The concept was defined in literature as early as 1947 in a study by Keeler (1947), 
however, it was not until later in the century that it began to be viewed as a viable 
treatment option for various genetic diseases (Osterman et al., 1970; Smithies et al., 
1985; Tatum, 1966). Gene therapy, in theory, offers a way to permanently correct 
disease-inducing mutations. As well the inserted transgene if integrated via specific 
targeting will exist under normal physiological regulation and will not interrupt other 
genes. Today there are many debilitating diseases being considered as candidates for 
treatment in gene therapy studies including cystic fibrosis (Mueller & Flotte, 2008), 
cancer (Aboody et al., 2008; Dachs et al., 2005; Spitzweg, 2009), ocular diseases 
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(Bainbridge et al., 2006), cardiovascular diseases (Lavu et al., 2011; Vinge et al., 2008), 
and haemophilia (Murphy & High, 2008). 
 
While the prospect of using HR-dependent gene targeting in a clinical setting for the 
correction of several disease-causing mutations within DNA holds much promise, the 
reality surrounding its actual implementation has been impeded by a few noted barriers 
including the low delivery and insertion efficiency of the corrected gene sequence into a 
cell’s DNA through targeted integration (de Semir & Aran, 2006; Iiizumi et al., 2008). 
An observed low gene targeting efficiency was noted in several early studies. Smithies et 
al. (1985) revealed a targeted integration frequency of 1 in 103 when a plasmid that 
homologously targeted the beta-globin loci in a human cell line was used. Similarly, in a 
mammalian cell study by Thomas et al. (1986), the correction of a point-mutated gene 
could be corrected after copies of the corrected gene were injected into the nucleus but 
only at a low frequency of 1 in 103 cells. Later studies and publications have also 
highlighted the observed occurrence of minimal gene targeting frequencies (Thomas & 
Capecchi, 1987; Vasquez et al., 2001; Yanez & Porter, 1998). Though the low gene 
targeting integration frequency has shown to be a significant challenge preventing the 
clinical implementation of gene therapy, another difficulty is the existence of random 
vector integrations occurring at an even higher rate than targeted integrations (Iiizumi et 
al., 2008; Roth & Wilson, 1985, 1986; Vasquez et al., 2001). A study done in Chinese 
hamster ovary (CHO) cells found that not only was there a low level of targeted 
recombinants, but these events occurred once for every 4000 events of non-targeted 
integration (Adair et al., 1989). It is thought that NHEJ is likely responsible for most of 
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these random integrations (Iiizumi et al., 2008), however, research suggests more 
homology is involved than one would expect to see if classical NHEJ was involved 
(Merrihew et al., 1996). A suggested contributing factor for both challenges has been the 
high reliance on NHEJ for DNA repair in the somatic cells of higher organisms (Fattah et 
al., 2008). So while the machinery for HR, a process key to successful integration in gene 
targeting, is available, the limited presence of HR appears to be a challenge for those 
working to improve gene targeting techniques (Fattah et al., 2008).   
 
In eukaryotic cells the presence of both NHEJ and HR DNA DSB repair mechanisms 
help maintain genomic stability.  While both are important for genomic stability, the 
relative proportion of each varies among different eukaryotic cells. Single-celled 
eukaryotic organisms DSB repair is dominated by HR events, but in multicellular 
eukaryotic organisms it is dominated by NHEJ events (Liang et al., 1998; Lieber, Yu, & 
Raghavan, 2006). The genomes of multicellular eukaryotes are notably more intricate and 
repetitive causing inefficient homology searches and making the genome more vulnerable 
to instability as a result of large genomic rearrangements (Gorbunova & Levy, 1999; 
Lieber & Karanjawala, 2004; Puchta, 2005). In addition, NHEJ is also a much faster 
process and has been estimated to take approximately 30 minutes while HR is a 
considerably longer process taking around seven hours to complete (Mao et al., 2008a). 
Thus the predominant usage of NHEJ can contribute to a less interrupted replication 
cycle. Together these make NHEJ an attractive repair pathway in mammalian cells, 
however, it has also consequently produced barriers for gene therapy implementation.  
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HR is a repair pathway that utilizes the presence of a homologous template to restore a 
DSB. As a result of the template utilization it has been deemed a relatively error-free 
process. DNA DSBs are detected by γH2AX that recruit repair factors to the break site 
including those involved in HR (Pardo et al., 2009; Paull et al., 2000). For HR in 
vertebrates the Mre11-Rad50-Nbs1 (MRN) complex is recruited early to resection the 
break ends and produce 3’ single-stranded DNA (ssDNA) overhangs (Misteli & 
Soutoglou, 2009). After the ends are processed, with the aid of Rad52 a ring-shaped 
oligomer and other members of the Rad family, the recombinase Rad51 is brought to the 
break site where it forms a right-handed helical polymer around the resected end to finish 
initiating the HR process. It is believed that the presynaptic nucleofilament randomly 
interacts with different regions of double-stranded (dsDNA) in its quest for homology. 
Once homology has been located, Rad51 and Rad52 facilitate the invasion of the 
homologous strand by the resected ssDNA end. Rad54, a member of the Swi2/Snf2 
superfamily, also interacts with Rad51 during this process and aids with the subsequent 
formation of the D-loop and Holliday junction as well as removing and recycling the 
recombinases once they have completed their respective tasks. Once contact between the 
homologous template and 3’ ssDNA overhang has been established DNA synthesis can 
copy the template strand and restore the information lost as a consequence of the break. 
Finally resolvases deconstruct the Holliday junction and return the strands to their 
original positions. Factors involved in the regulation of this process include replication 
protein A (RPA), a ssDNA binding protein that can either inhibit or stimulate the binding 
of Rad51 to ssDNA based on its relative abundance at the break site, and BRCA2, a 
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recombinase accessory factor that has been suggested to direct Rad52 to the nucleus and 
override RPA inhibition (Dudas & Chovanec, 2004; Filippo et al., 2008). 
 
NHEJ on the other hand has little regard for homology and consequently has been labeled 
an error-prone process (Heidenreich et al., 2003). Some of the key proteins that have 
been implicated in NHEJ are Ku, DNA-dependent protein kinase catalytic subunit (DNA-
PKCS), Artemis, XRCC4, XLF, and DNA ligase IV (LigIV) (Iiizumi et al., 2008). The 
mechanism behind NHEJ is believed to be comprised of an initial recruitment of the 
heterodimer Ku protein that is composed of Ku70 and Ku80 to the ends of the DSB 
(Iiizumi et al., 2008). This stabilizes the broken strand and results in the association of the 
DNA-PKcs with the protein Artemis to form the active DNA-PK (DNA-dependent 
protein kinase) (Singleton et al., 1999). DNA-PK acts to process the ends and to prepare 
them for ligation (Iiizumi et al., 2008; Karran, 2000). In the subsequent ligation stage 
XRCC4, a cofactor for DNA ligase IV, is enlisted to the site of DNA damage by Ku and 
phosphorylated by DNA-PK (Grawunder et al., 1997; Rapp & Greulich, 2004). It pairs 
with the protein XLF and then associates with DNA ligase IV to complete the DSB repair 
(Ahnesorg et al., 2006; Iiizumi et al., 2008). We have chosen to focus on Ku70 and 
DNA-PKCS because past research has shown its manipulation to be more effective in 
altering DSB repair than the manipulation of other NHEJ factors (Pierce et al., 2001). 
They also have been theorized to be involved in direct competition with HR factors for 
the ends of DSBs (Fattah et al., 2008). 
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With the knowledge that at least two separate mechanisms exist for DNA DSB repair in 
eukaryotic cells have come investigations into the mechanisms mediating entry into 
either HR or NHEJ. It is established that there is some cell cycle dependence mediating 
this choice (Hochegger et al., 2004). NHEJ is the dominant DSB repair pathway in 
mammalian cells and the dominance is even more pronounced in the resting, G1, and 
early S phase. In the late S phase and G2 phase the level of HR repair rises as the 
existence of two sister chromatids emerge. These conclusions have been supported by 
studies looking at the outcomes of IR-induced DSBs in HR and NHEJ deficient cell lines 
at different stages of the cell cycle. In chicken DT40 cells, those deficient in Ku70 
showed increased IR-sensitivity in the G1 to early S phase indicating that NHEJ plays an 
important role during this period of the cell cycle (Bezzubova et al., 1997; Takata et al., 
1998). Conversely, DT40 cells deficient in Rad54 have increased sensitivity to IR during 
the late S and G2 phases highlighting the importance of HR during these times. 
Supporting this is the observation that concentrations of cyclin-dependent kinases 
(CDKs) are low in S phase. CDKs have been shown to phosphorylate BRCA2, a HR 
protein, and prevent them from interacting with Rad51 (Pardo et al., 2009). In addition, 
cells deficient in both Ku70 and Rad54 showed a higher degree of IR-sensitivity in G2 
phase than is seen in either single mutant indicating some overlap may exist between the 
two repair mechanisms.  Studies in both mice and humans have shown similar findings 
(Cheong et al., 1994; Fukushima et al., 2001; Takashima et al., 2009; Valerie & Povirk, 
2003). Another mechanism closely tied to cell cycle regulation that appears to mediate 
the entry into either NHEJ or HR is DNA end resection (Aylon et al., 2004; Jazayeri et 
al., 2006; Pardo et al., 2009). Marginal resectioning is sufficient for NHEJ while more 
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extensive 5’ DNA end resectioning initiates HR and impedes NHEJ (Pardo et al., 2009).  
Recently an in vitro system using a forked dsDNA substrate was utilised to investigate 
the interactions between purified human Ku, Mre11, Mre11-Rad50-Xrs2 (MRX) 
complex, and exonuclease 1 (Sun et al., 2012). The study revealed that Ku can block the 
resection of the forked dsDNA substrate. Once Ku is bound, MRX is not able to bind or 
displace Ku. Recently it has been shown that a Ku homolog which binds indefinitely to 
DNA ends can lead to decreases in resection of DNA ends and consequently - HR (Shao 
et al., 2012). Accordingly, it has been proposed that some degree of direct cooperation 
and competition between these two repair pathways may exist (Sonoda et al., 2006).  
 
Cooperation and competition between HR and NHEJ are important and essential. The 
elimination of one or the other can have detrimental consequences for developing 
organisms (Orii et al., 2006), and as has already been suggested sometimes the 
prevalence of one or the other can bestow certain advantages to the organism. 
Components from both pathways can congregate at the same DSB sites (Rapp & 
Greulich, 2004; Richardson & Jasin, 2000). Co-localization, FRET imaging, & co-
immunoprecipitation techniques in HaCaT cells with UV-A induced DSBs have provided 
evidence for the association and potentially even cooperation between proteins from both 
pathways at these sites (Rapp & Greulich, 2004). As well the concurrent loss of proteins 
from both repair pathways results in more severe phenotypes than the loss of a key player 
from one individual pathway (Couedel et al., 2004; Mills et al., 2004). Mice lacking both 
LigIV and Rad54 are more severely impaired in proliferation, unrepaired DSBs, and 
genomic instability (Mills et al., 2004). However, several studies have suggested that 
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while cooperation between the two may be present, competition plays a large part. In a 
study with the DT40 cell line, when cells were deficient in Ku70 the level of HR 
increased in response to restriction enzyme induced DSBs by I-SceI (Fukushima et al., 
2001). In addition, a DNA-PKCS DSB repair deficiency could be relieved to some degree 
with the simultaneous reduction in Ku70 suggesting that Ku70 prevents other DSB repair 
pathways from functioning at the break site. Comparable results were seen in another 
study involving DT40 cells (Adachi et al., 2001). As well findings involving mouse 
embryonic cells support these results (Frank-Vaillant & Marcand, 2002; Pierce et al., 
2001). Another study showed that HR can be inhibited by Ku when it is stabilized by 
Lif1 (Zhang et al., 2011). In support of competition existing between the two pathways is 
the observation that NHEJ factors like Ku70 are more abundant in the cell (Haber, 2000; 
Jackson & Bartek, 2009) and are recruited to the DSBs more rapidly than HR factors 
(Kim et al., 2005). Both implicate NHEJ as the key competitive DSB repairing process in 
mammalian cells. 
 
Two predominant DNA DSB repair pathways exist – one of which is involved in 
mediating gene therapy. As a result of evidence that implicates some degree of 
competition between the two, one line of thought for improving gene targeting methods 
has been geared towards shifting the natural balance between the two major DNA repair 
mechanisms away from NHEJ and towards HR (de Boer et al., 2010; Fattah et al., 2008; 
Iiizumi et al., 2008; Pierce et al., 2001). Some approaches to accomplish this have been 
the up-regulation of genes related to HR, the down-regulation of genes related to NHEJ, 
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or even theoretically the simultaneous use of both (de Boer et al., 2010; Fattah et al., 
2008; Iiizumi et al., 2008; Pierce et al., 2001).  
 
Two of the key proteins implicated early in NHEJ are Ku70 and DNA-PKCS. The current 
study focuses on these two proteins because of their early role in NHEJ DSB repair. 
Moreover there have been several studies linking down-regulation of Ku70 and DNA-
PKCS in different eukaryotes to decreased NHEJ, increased HR, and in some cases an 
increased gene targeting frequency (Alshahni et al., 2011; Fattah et al., 2008; Pierce et 
al., 2001; Secretan et al., 2004; Zhang et al., 2011). 
 
Several studies to date have targeted the reduction of Ku. A study in mammalian 
embryonic stem cells deficient in either Ku70, XRCC4, or DNA-PKCS found that in all 
mutants, but especially those lacking Ku70, the frequency of HR increased (Pierce et al., 
2001). However, the same study showed sister chromatid exchange and gene targeting 
frequency remained unaffected. In another study involving filamentous yeast the deletion 
of Ku70 and LigIV resulted in an increased gene targeting frequency at three separate 
loci to nearly 70%. Comparable findings have been seen in several other studies with 
yeast (Abdel-Banat et al., 2010; Alshahni et al., 2011; Arentshorst et al., 2012; Wang et 
al., 2011; Wesolowski-Louvel, 2011; Zhang et al., 2011). Another experiment utilized 
recombinant adeno-associated virus (rAAV) as a gene targeting vehicle to manufacture 
Ku70 deficient human somatic cells (Fattah et al., 2008). While Ku70+/- cells were 
successfully generated, all attempts to generate Ku70-/- cells were unsuccessful. Despite 
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unsuccessfully creating Ku70-/- cells, unexpectedly it was discovered that Ku70+/- cells 
yielded a 5 to 10 times higher gene targeting frequency than the wild type at multiple 
different loci. In addition the use of other techniques to deplete the level of Ku70 showed 
similar elevated gene targeting frequencies. In 2004, a study in mammalian cells with 
mutations in either Ku86 or DNA-PKCS revealed NHEJ in Ku86-null cells was 
compromised, however, levels returned to normal when the cells were rescued with Ku86 
(Secretan et al., 2004). Evidence of increased microhomology use was also seen at NHEJ 
sites along with an overall increased frequency of DNA insertions. Evidence indicates 
that at the same time the number of random integrations consequently decreases 
(Hamilton & Thacker, 1987; Jeggo & Smithravin, 1989; Vasquez et al., 2001). DNA-
PKCS-null mammalian cells revealed no changes in HR and NHEJ levels indicating there 
may be a DNA DSB repair mechanism that does not require DNA-PKCS, but does depend 
on the presence of Ku (Secretan et al., 2004). Together these studies support the 
conclusion that Ku plays a crucial role in the NHEJ mechanism and implicates reductions 
in its presence with positive consequences for HR and gene targeting frequencies. 
 
Along with some of the studies already described other research has also been done to 
investigate the effects of lowering DNA-PKCS levels in cells. In CHO cells a DNA-PKCS 
deficiency lead to an increase in HR that could be reversed with DNA-PKCS 
complementation (Allen et al., 2002; Delacote et al., 2002; Shrivastav et al., 2009). DNA-
PKCS inhibition induced by DNA-PKCS kinase inhibitors, conversely, have been shown to 
decrease HR levels and increase IR sensitivity due to overall decreased DSB repair 
(Allen et al., 2002). The deficient repair potentially may be a result of an inability to 
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remove DNA-PKCS from the DSB ends leaving them unavailable to repair proteins from 
other pathways (Allen et al., 2003). This is echoed by severe DSB repair impairments in 
rAAV-constructed DNA-PKCS-deficient human somatic cells (Fattah et al., 2010). 
Because HR increases in the absence of DNA-PKCS but decreases in the presence of 
catalytically dysfunctional DNA-PKCS, it suggests there is some direct competition for 
DSB ends between HR and NHEJ. Another study revealed gene therapy could 
successfully be used to correct a point mutated DNA-PKCS gene in thymoma T cells from 
severe combined immunodeficient (SCID) mice (Zayed et al., 2006).  
 
The connection between DNA-PKCS and HR has also been investigated. Neal et al. 
(2011) showed that increasing amounts of DNA-PKCS expression plasmids increased HR 
suppression in DNA-PKCS-deficient CHO cells containing a HR substrate. Furthermore, 
the study uncovered that phosphorylation of certain sites on DNA-PKCS could influence 
DSB repair choice by stimulating HR and deterring NHEJ (Neal et al., 2011). This study 
demonstrates changing DNA-PKCS levels can have repercussions for DSB repair pathway 
choice and corroborate the manipulation of DNA-PKCS as an approach to shift the 
balance between HR and NHEJ.  
 
While the focus has been on the consequences of Ku and DNA-PKCS level manipulation, 
other NHEJ proteins can also influence the prevalence of the different DSB repair 
mechanisms and further provide validation for using such an approach to shift the 
balance between HR and NHEJ.  LigIV -/- chicken DT40 and human Nalm-6 cell lines 
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displayed elevated gene targeting levels (Iiizumi et al., 2008). In DT40 cells this was 
accompanied by a reduction in random integrations. The same reduction in random 
integrations was also implicated in mouse LigIV-/- cells, but was not seen in Nalm-6 
cells indicating some repair mechanism other than NHEJ may be responsible for them 
(Sado et al., 2001). In human cells a XRCC4-deficiency has been linked to severe DNA 
DSB impairments (Katsube et al., 2011), however, evidence in CHO cells suggests this 
impairment may be accompanied by a reduction in random integration events (Hamilton 
& Thacker, 1987; Jeggo & Smithravin, 1989; Vasquez et al., 2001). A mutation in 
XRCC4 has been shown to increase HR events (Delacote et al., 2002). In human somatic 
cells recombinant adeno-associated virus (rAAV) was used to manufacture Ku86, DNA-
PKCS, XLF, and LigIV deficiencies (Fattah et al., 2010). Severe reductions in DNA DSB 
repair were detected in cells lacking DNA-PKCS, XLF, and LigIV. Interestingly in cells 
lacking Ku86 wild-type levels of NHEJ were observed, however, repair events were 
largely governed by microhomology. When the cells deficient in DNA-PKCS and LigIV 
were paired with reduced levels of Ku70 the number of NHEJ frequency events increased 
and was also governed predominantly by microhomology. This evidence implicates the 
presence of another NHEJ pathway in the absence of the Ku-dependent NHEJ repair. 
 
The notion that a back-up NHEJ (B-NHEJ) repair pathway exists has gained momentum 
over the last decade and appears to have implications for gene targeting efficiency 
(Bennardo et al., 2008; Iliakis, 2009; Mladenov & Iliakis, 2011; Perrault et al., 2004; 
Rass et al., 2012; Wang et al., 2003). B-NHEJ was originally proposed to explain DSB 
repair that could not be attributed to either classical NHEJ (C-NHEJ) or HR (Perrault et 
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al., 2004; Secretan et al., 2004; Sonoda et al., 1998; Wang, Zeng, Bui, DiBiase, et al., 
2001; Wang, Zeng, Bui, Sonoda, et al., 2001). Even in the absence of NHEJ and HR, the 
majority of DNA DSBs are still repaired albeit at a slower rate (Wang, Zeng, Bui, 
DiBiase, et al., 2001; Wang, Zeng, Bui, Sonoda, et al., 2001). Unlike the C-NHEJ 
pathway that involves limited end processing and no homology utilization, the proposed 
back-up involves end resectioning and regular use of microhomologies (Rass et al., 
2012). B-NHEJ is considered a decidedly mutagenic pathway because it is often 
associated with genomic deletions and may be responsible for the error prone nature 
previously attributed to classical NHEJ (C-NHEJ) (Rass et al., 2012). Also, unlike C-
NHEJ it is active primarily in the G2 phase (Wu et al., 2008). B-NHEJ also appears to 
work independently of the factors involved in C-NHEJ. Instead it has been linked to 
DNA Ligase III (LigIII), Poly [ADP-ribose] polymerase 1 (Parp-1), and histone H1 
(Audebert et al., 2004; Iliakis, 2009; Mladenov & Iliakis, 2011; Wang et al., 2005). 
However, C-NHEJ proteins like Ku are believed to interact and influence B-NHEJ 
(Ariumi et al., 1999; Bennardo et al., 2008; Hochegger et al., 2006; Li et al., 2004; Saberi 
et al., 2007).  
 
Parp-1 is part of the poly(ADP-ribosyl)ation polymerase (PARP) superfamily. 
Poly(ADP-ribosyl)ation involves the addition of ADP-ribose molecules as a post-
translational modification that targets histones and various other nuclear proteins in 
response to breaks in DNA (Ame et al., 2004). As previously mentioned Parp-1 has been 
implicated in the proposed B-NHEJ pathway. It arrives at DNA breaks early and there is 
evidence of interactions between Parp-1 & NHEJ proteins (Ame et al., 2004; Sonoda et 
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al., 2006). In DT40 cells, immunoprecipitation of a non-DNA binding domain belonging 
to Parp-1 pulls down Ku70 and DNA-PK (Paddock et al., 2011). Furthermore Parp-1-/- 
results in diminished gene conversion but is restored with the depletion of Ku70 or LigIV 
indicating Parp-1 may influence NHEJ proteins (Paddock et al., 2011). The interaction is 
strengthened by electrophoretic mobility shift assays done using radioactively labelled 
DNA DSB substrate incubated with Ku and Parp-1 (Wang et al., 2006). Evidence 
indicated that Ku binds with 10-fold higher affinity than Parp-1, however, as the 
concentration of Parp-1 increases, increasing amounts of Ku are displaced from the DSB 
ends. Other studies also provide evidence of interaction between Parp-1 and NHEJ 
proteins (Ariumi et al., 1999; Galande & Kohwi-Shigematso, 1999; Li et al., 2004).  
 
Parp-1 may also play role in HR, specifically by mediating the competition between Ku 
and the HR mechanism (Hochegger et al., 2006; Satoh & Lindahl, 1992; Satoh et al., 
1993; Shall, 1995). In chicken DT40 cells, the absence of Parp-1 led to decreased HR 
levels while the concurrent absence of Parp-1 and Ku70 were implicated in HR increase 
and resistance to DNA damaging agents (Hochegger et al., 2006).  Parp-1 chemical 
inhibition and depletion using shRNA has been linked to the improvement of AAV 
integration into the AAV genome a process linked to HR (Romanova et al., 2011). B-
NHEJ may also be involved in random integrations previously attributed to C-NHEJ. 
Random integrations involve more homology than would be expected for C-NHEJ, a 
marker that often accompanies B-NHEJ (Merrihew et al., 1996). Inhibition of poly(ADP-
ribosyl)ation resulted in decreased random integration and improved gene targeting 
frequency at the APRT locus in a CHO cell line (Waldman et al., 1996). The conclusions 
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drawn establish a role for Parp-1 in DNA DSB repair and potentially as a candidate for 
improving gene targeting. 
 
The focus of the presented study was to observe the effects of down-regulating Ku70, 
DNA-PKCS, and Parp-1 on the balance between NHEJ and HR DSB repair in mammalian 
somatic cells. Two fibroblast cell lines containing a GFP reporter cassette for either 
NHEJ or HR were utilized (Mao et al., 2008a; Mao et al., 2008b; Waldman et al., 1996). 
Upon induction of an artificial DSB, only the appropriate repair mechanism restored a 
functional GFP gene. Anti-Ku70, anti-DNA-PKCS, and anti-Parp-1 antibodies were 
introduced into the cells lines and subsequent shifts in the DSB repair balance were 
quantified using flow cytometry. Because the natural frequency of HR, the mechanism 
responsible for gene targeting, is relatively low in somatic human cells it has been 
hypothesized that an increase in HR frequency would contribute to an increase in the 
gene targeting frequency and thus lead to improved gene targeting techniques (Fattah et 
al., 2008). The objective of this experiment was primarily to manipulate the balance of 
DNA repair within human cells so that it shifts away from NHEJ and towards HR in 
order to increase the gene targeting frequency. 
 
 
By introducing anti-Ku70 antibodies and anti-DNA-PKCS into mammalian cells, it is 
suspected there will be limitations placed on the amount of Ku70 and DNA-PKCS that is 
available for the NHEJ mechanism. It is predicted that limiting the resources necessary 
for NHEJ will result in a decreased frequency of NHEJ and a subsequent compensatory 
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increased frequency of HR.  The use of antibodies would make this shift temporary to 
circumvent the negative repercussions associated with permanent NHEJ deficits and 
cause only a limited upset in this balance to occur. It is also predicted that this temporary 
shift between the DNA repair mechanisms will translate into a temporary shift towards an 
increase in gene targeting frequencies given the relationship between gene targeting and 
HR. 
 
The introduction of anti-Parp-1 antibodies will also be tested. Based on previous 
evidence, it is predicted the downregulation of Parp-1 using antibodies will result in a HR 
decrease, however, when paired with anti-Ku antibodies an increase in HR is predicted. 
As was the case with the use of antibodies to downregulate Ku and DNA-PKCS, the 
temporary nature of this approach is attractive because it minimizes the long-term effects 
associated with the permanent depletion of this repair protein. Similarly to the use of anti-
Ku and anti-DNA-PKCS, the manipulation of HR levels in response to anti-Parp-1 
antibodies in combination with anti-Ku70 antibodies may have positive repercussions for 
gene targeting in cells. 
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Chapter 2: Materials and Methods 
 
2.1 General Protocols 
 
Cell Culture – HEK293  
Human wildtype HEK293 cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) High Glucose (Life Technologies) supplemented with 10% fetal bovine serum 
(FBS; Thermo Scientific) and 100 U/ml penicillin-streptomycin (Sigma). Cells were 
grown in a humidified incubator maintained at 6% CO2 with a temperature of 37°C. 
 
Cell Lines/Constructs Used – HI5c and I9a 
Immortalised human foreskin fibroblast cell lines, HCA2-hTERT, containing either a 
reporter cassette for HR or NHEJ, H15c and I9a respectively, were obtained from Dr. 
Gorbunova’s Lab (University of Rochester). Cells were grown in Eagle’s Minimum 
Essential Medium (ATCC) containing Earles Balanced Salt Solution supplemented with 
15% fetal bovine serum (FBS; Thermo Scientific) and 100 U/ml penicillin-streptomycin 
(Sigma). Growth conditions were kept constant at 6% CO2 and 37°C. 
 
These reporter cassettes were designed to detect DSB repair events allowing for the 
quantification of shifts in the frequency of both HR and NHEJ upon the introduction of 
antibodies against DSB repair proteins. The HR reporter construct integrated into the 
genome of HCA2-hTERT cells contains two mutated copies of the GFP gene under the 
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control of a CMV promoter (Mao, et al., 2008a, 2008b)(Figure 2.1). One copy is 
disrupted by a stuffer sequence that contains a 22 nucleotide deletion in addition to the 
insertion of two I-SceI recognition sites in inverted orientation to one another. The second 
copy is truncated and lacks the ATG transcriptional start codon. Only DSBs repaired by 
HR will result in the restoration of a functional GFP gene. The NHEJ reporter cassette 
consists of a GFP gene containing an intron from the rat Pem1 gene which has been 
interrupted by an adenoviral exon that is flanked by I-SceI recognition sites in direct 
orientation to one another (Mao et al., 2008a, 2008b)(Figure 2.2). Following induction of 
DSBs by I-SceI, repair by NHEJ will result in GFP expression. To induce DSBs within 
these cell lines an I-SceI coding vector was used. 
 
Splitting Cells 
Cells were grown to target confluency in 10 cm cell culture plates (Sarstedt), the media 
was removed and the cells were washed with 4 ml of 1x Dulbecco’s Phosphate Buffered 
Saline (DPBS) (Lonza BioWhittaker). Cells were treated with 1 ml of 1x Trysin EDTA 
(cellgro) and then incubated at 37°C for 2-5 minutes. The appropriate media for the cell 
line was used to wash the bottom of the plate and evenly suspend the cells. The cells were 
then transferred to new culture plates or well plates. 
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Transfections  
Cells were grown and then divided into well plates 24 hours prior to transfection. When 
using Lipofectamine 2000 (Life Technologies), transfection was done at a confluency of 
about 90%.  All treatment samples were transfected using 10 µl of Lipofectamine 2000 
(Life Technologies). Chariot (Active Motif) transfections were done when cells were 
about 40-50% confluent and 6 µl of Chariot (Active Motif) was used per transfection 
sample. When using Lipofectamine LTX with PLUS Reagent (Life Technologies) or 
TranSIT LT1 (Mirus), transfection was done at a confluency of about 90%. Unless 
specified, treatment samples were transfected using 1 µl of PLUS Reagent (Life 
Technologies) and 5 µl of Lipofectamine LTX (Life Technologies). If using TranSIT 
LT1 (Mirus), treatment samples were transfected into cells using 0.3 µl of transfection 
reagent per 100 µl of DNA. Cells were otherwise transfected as per the transfection 
reagents respective instructions. Cells were incubated at 6% CO2 and 37°C. Triplicates 
were used for each experimental and control treatment. 
 
Harvesting Cells – 6-Well Plates (9.6 cm2/well) 
Twenty-four hours after transfection, cells were harvested. The media was removed and 
the cells were washed with 1 ml of 1x DPBS. Cells were treated with 200 µl of 1x Trysin 
EDTA (cellgro) and then incubated at 37°C for 2-5 minutes. The trypsinized cells were 
washed with 3 ml of appropriate media to evenly suspend the cells. The resuspended cells 
were centrifuged at 4ºC, 3000 rpm for 5 minutes. The media was removed and the cells 
were resuspended in 10 ml of 1x DPBS then centrifuged again at 4ºC, 3000 rpm for 5 
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minutes. The DPBS was removed, the cells were resuspended in 2 ml of 1x DPBS, and 
then kept on ice.  
 
Harvesting Cells – 24-Well Plates (2 cm2/well) 
Twenty-four hours after transfection, cells were harvested. The media was removed and 
the cells were washed with 0.5 ml of 1x DPBS. Cells were treated with 50 µl of 1x Trysin 
EDTA (cellgro) and then incubated at 37°C for 2-5 minutes. The trypsinized cells were 
washed with 1 ml of appropriate media to evenly suspend the cells. The resuspended cells 
were centrifuged at 4ºC, 1400 rpm for 5 minutes. The media was removed and the cells 
were resuspended in 1 ml of 1x DPBS then centrifuged again at 4ºC, 1400 rpm for 5 
minutes. The DPBS was removed, the cells were resuspended in 0.5-1 ml of 1x DPBS, 
and then kept on ice.  
 
FACS Analysis 
Cells were kept on ice prior to flow cytometer analysis. FACS analysis was done with a 
BD FACSCanto II flow cytometer. Gating was established using cells only, control 
plasmid only, gWIZ-GFP (Genlantis) only, and transfection control only treatments when 
available (Figure 2.3). In cases where there was no gWIZ-GFP only or transfection 
control plasmid only treatment, gating was done to diagonally split the scatterplot in half 
around the cells only or control plasmid treatments (Figure 2.3). A FITC versus PE 
fluorescence or FITC versus APC fluorescence scatterplot was used to analyse the cells. 
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Viability was determined by gating around the prominent population of expected size on 
a SSC versus FSC scatterplot. Viability was only calculated in experiments that analysed 
all events rather than just the viable events. Experiments where only the viable events 
were analysed are indicated as such. A minimum of 10000 events were analysed for each 
treatment sample. The software utilised for FACS analysis was BD FACSDiva Software 
v6.1.3.  
 
General Data Analysis 
To counteract the normal differences in transfection efficiencies between treatment 
samples, normalisation was done using the levels of transfection control plasmid 
expression. A consistent amount of control plasmid was transfected into each 
experimental treatment. After data collection, the percentages of both GFP and DsRed or 
APC positive events for each sample were converted to decimal fractions. The calculated 
fraction of GFP positive events was then divided by the fraction of DsRed or APC 
positive events. This value was termed the relative amount of GFP positive events. 
Normalisation was only done in treatments where a consistent amount of the transfection 
control was present. 
 
Statistical Analysis 
For each treatment group consisting of more than one treatment sample, the mean and 
standard deviation were calculated (Microsoft Excel for Mac 2011). One-tailed unpaired 
t-tests were used to determine the statistical significance of the experimental data when 
no change was expected between treatments (Microsoft Excel for Mac 2011). Two-tailed 
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unpaired t-tests were used to determine the statistical significance of the experimental 
data when either an increase or decrease in the data was expected (Microsoft Excel 
2011).  
 
 
2.2 Delivery of gWIZ-GFP and Antibodies Against GFP into HEK293 Cells 
The purpose of introducing both gWIZ-GFP (Genlantis) and antibodies against GFP was 
to demonstrate through flow cytometry that antibodies could be delivered simultaneously 
with plasmids into cells. pDsRed-Express2-N1 (Clontech) was used as a transfection 
control. Mouse monoclonal IgG2a GFP (B-2) antibodies were used (Santa Cruz 
Biotechnology). 
 
 
Testing the transfection efficiency of gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 
(Clontech) in HEK293. 
Four different treatments were done: cells only, 300 ng of gWIZ-GFP (Genlantis), 300 ng 
of pDsRed-Express2-N1 (Clontech), and 300 ng of control plasmid (pZP500). Cells were 
split into 6-well plates and transfected using Lipofectamine 2000 (Life Technologies). 
Following a 24 hour post-transfection incubation period, all treatment samples were 
harvested and immediately analysed on a BD FACSCanto II flow cytometer.  
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Comparing the utilisation of Lipofectamine 2000 (Life Technologies) and Chariot (Active 
Motif) as transfection reagents in HEK293. 
Experiment 1: 
Lipofectamine 2000 (Life Technologies) was used to transfect 300 ng of control plasmid 
(pZP500), 300 ng of each gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 (Clontech), 
or 300 ng of each gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 (Clontech) in 
addition to 2 µg, 4 µg, or 6 µg of anti-GFP antibodies into HEK293 cells (Table 2.1). 
Three other treatments were done – one using both Lipofectamine 2000 (Life 
Technologies) and Chariot (Active Motif) and the other two using only Chariot (Active 
Motif) (Table 2.1). In the treatment that used both transfection reagents, Lipofectamine 
2000 (Life Technologies) was used to introduce 300 ng of each gWIZ-GFP (Genlantis) 
and pDsRed-Express2-N1 (Clontech) into the cells and 21 hours later Chariot (Active 
Motif) was used to introduce 3 µg of anti-GFP antibodies into the cells (Table 2.1). This 
treatment was transfected with Lipofectamine 2000 (Life Technologies) when cells were 
70% confluent instead of 90% because Chariot (Active Motif) is more successful when 
applied to cells at a lower confluency. In the Chariot (Active Motif) only treatment, 300 
ng of each gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 (Clontech) in addition to 3 
µg of anti-GFP antibodies was used. Cells were split into 6-well plates. Twenty-four 
hours later the Lipofectamine 2000 (Life Technologies) treatment samples were 
transfected and then an additional 21 hours later the Chariot (Active Motif) treatment 
samples were transfected. Cells were harvested 24 hours after transfection of the 
Lipofectamine-treated treatment samples and 3 hours after transfection of the Chariot 
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(Active Motif)-treated treatment samples. All treatment samples were harvested and 
immediately analysed on a BD FACSCanto II flow cytometer. 
 
Experiment 2: 
In a second experiment, the following treatments were done in HEK293 using 
Lipofectamine 2000 (Life Technologies) and Chariot (Active Motif) as transfection 
reagents: cells only, 300 ng of control plasmid (pZP500), 300 ng of each gWIZ-GFP 
(Genlantis) and pDsRed-Express2-N1 (Clontech), and 300 ng of each gWIZ-GFP 
(Genlantis) and pDsRed-Express2-N1 (Clontech) in addition to 1µg of anti-GFP 
antibodies (Table 2.2). Two additional treatments for Chariot (Active Motif) contained 
300 ng of each gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 (Clontech) as well as 
either 2 µg or 4 µg of anti-GFP antibodies (Table 2.2). Cells were split into 6-well plates. 
Twenty-four hours later the Lipofectamine-transfected treatment samples were 
transfected and then an additional 21.5 hours later the Chariot (Active Motif) treatments 
were transfected. The media was changed for the Chariot (Active Motif)-treated 
treatment samples 0.5 hours after their transfection and then incubated for an additional 2 
hours. Cells were harvested 24 hours after transfection of the Lipofectamine-treated 
treatment samples and 2.5 hours after transfection of the Chariot (Active Motif)-treated 
treatment samples. All treatment samples were harvested and immediately analysed on a 
BD FACSCanto II flow cytometer. 
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Determining the success of anti-GFP antibody delivery via Lipofectamine 2000 (Life 
Technologies) through observations of GFP fluorescence changes. 
Experiment 1:  
HEK293 cells were transfected in 6-well plates with the following different experimental 
control treatments: cells only, 300 ng of control plasmid (pZP500), 300ng of pDsRed-
Express2-N1 (Clontech), and 300ng of both gWIZ-GFP (Genlantis) and pDsRed-
Express2-N1 (Clontech) (Table 2.3). Experimental treatments were comprised of 300ng 
of gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 (Clontech) in addition to either 1 
µg, 2 µg, or 5 µg of anti-GFP antibodies (Table 2.3). Cells were split into 6-well plates 
and then transfected with the respective treatments using Lipofectamine 2000 (Life 
Technologies). All treatment samples were harvested after 24 hours and immediately 
analysed on a BD FACSCanto II flow cytometer. 
 
Experiment 2:  
The experiment was done similar to Experiment 1, however a few revisions were made 
(Table 2.4). Cells were split into 24-well plates instead of 6-well plates. Two additional 
experimental control treatments were done. One contained 300 ng of gWIZ-GFP 
(Genlantis) only and the other had 5 µg of anti-GFP antibody, 300 ng of gWIZ-GFP 
(Genlantis) and pDsRed-Express2-N1 (Clontech), and no transfection reagent (Table 
2.4). The cells only control was removed. All treatment samples were harvested in 700 µl 
of 1x DPBS containing 2% FBS. The centrifugation conditions during harvest were room 
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temperature, 1400 rpm for 5 minutes. A minimum of 20000 viable cells were analysed 
per treatment sample on the BD FACSCantoII flow cytometer.  
 
Experiment 3:  
The experiment was done similar to Experiment 2 (Table 2.4). The only two changes 
were the utilisation of 6-well plates instead of 24-well plates and a minimum of 20000 
events consisting of both viable and nonviable events were analysed per treatment 
sample.  
 
 
2.3 Delivery of I-SceI Expression Vector and Antibodies Against DSB DNA Repair 
Factors into HI5c and I9a Cells 
 
An I-SceI expression vector and antibodies against DSB DNA repair factors were 
transfected into HI5c and I9a to demonstrate through changes in GFP fluorescence how 
antibodies affect levels of HR and NHEJ in mammalian cells. The I-SceI expression 
vector was generously provided by the Gorbunova Lab (University of Rochester). 
Sequencing had previously been done to verify the expression vector. Mouse monoclonal 
IgG2b to Ku70 [N3H10] and mouse monoclonal IgG1 to DNA-PKCS [18-2] antibodies 
from abcam were used. Additionally, mouse monoclonal IgG2a to PARP-1 (F-2) 
antibodies (Santa Cruz Biotechnology) were used.  
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The transfection success of Lipofectamine 2000 (Life Technologies), Lipofectamine LTX 
with PLUS Reagent (Life Technologies), and TranSIT LT1 (Mirus) in HI5c and I9a. 
Experiment 1: 
In HI5c cells the following control treatments were transfected into cells using 
Lipofectamine 2000 (Life Technologies): cells only, 300 ng of pDsRed-Express2-N1 
(Clontech), and 300 ng of gWIZ-GFP (Genlantis). In experimental treatments, 300 ng of 
pDsRed-Express2-N1 (Clontech) was co-transfected with 300 ng, 600 ng, or 1200 ng of 
I-SceI expression vector. Transfections were conducted in 6-well plates. After the post-
transfection incubation, cells were harvested and immediately analyzed by flow 
cytometry. There were two replicates done per treatment. 
 
Experiment 2: 
HI5c and I9a cells were each split into 6-well plates and transfected using Lipofectamine 
2000 (Life Technologies). A cells only treatment was used as a control in each cell line. 
Experimental treatments consisted of either 300 ng, 600 ng, or 1200 ng of pDsRed-
Express2-N1 (Clontech) or 300 ng, 600 ng, or 1200 ng of gWIZ-GFP (Genlantis). After 
the post-transfection incubation, cells were harvested and immediately analyzed by flow 
cytometry. There were two replicates done per treatment. 
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Experiment 3: 
HI5c and I9a cells were split into 24-well plates and 24 hours later transfected with either 
Lipofectamine LTX with PLUS Reagent (Life Technologies) or TranSIT LT1 (Mirus). 
TranSIT LT1 (Mirus) transfections were done using 3 µl of the transfection reagents. 
Both transfection reagents were used to deliver the following treatments into both cell 
lines: cells only, 500 ng of pDsRed-Express2-N1 (Clontech), and 500 ng of both 
pDsRed-Express2-N1 (Clontech) and I-SceI expression vector. Twenty-four hours after 
transfection, cells were harvested and immediately analyzed by a BD FACSCanto II flow 
cytometer. The centrifugation conditions during harvest were 2000 rpm at 4ºC for 5 
minutes. 
 
Determining the optimal incubation time between transfection and harvest in HI5c and 
I9a. 
Cells were grown and split into 24-well plates. The experimental control treatments used 
included: 600 ng of control plasmid (pZP500), 600 ng of pDSRed-Express2-N1 
(Clontech), and 600 ng of gWIZ-GFP (Genlantis) (Table 2.5). Two experimental 
treatments were done. The first contained 50 µl of pDsRed-Express2-N1 (Clontech) and 
550 µl of I-SceI expression vector (Table 2.5). The second contained 100 µl of pDSRed-
Express2-N1 (Clontech) and 1100 µl of I-SceI expression vector (Table 2.5). Each 
experimental control treatment and experimental treatment was harvested at three 
different time points – 24 hours post-transfection, 48 hours post-transfection, and 72 
hours post-transfection. Treatment samples were transfected using TranSIT LT1 (Mirus). 
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All treatment samples were harvested in 500 µl of 1x DPBS containing 2% FBS. A 
minimum of 20000 cells were analysed per treatment sample on the BD FACSCantoII 
flow cytometer.  
 
Comparing the transfection success of two potential control plasmids -- pDsRed-
Express2-N1 (Clontech) and pCMV-Neo-Bam APC (Addgene) – in HI5c and I9a.  
HI5c and I9a cells were grown and split into 24-well plates. Five different control 
treatments were used: cells only, 600 ng of pDsRed-Express2-N1 (Clontech), 600 ng of 
pCMV-Neo-Bam APC (Addgene), 600 ng of I-SceI expression vector, or 600 ng of 
gWIZ-GFP (Genlantis) (Table 2.6). Experimental treatments utilized either pDsRed-
Express2-N1 (Clontech) or pCMV-Neo-Bam APC (Addgene) as a control plasmid when 
transfecting I-SceI expression vector into I9a and HI5c cells in ratios of either 300 ng of 
control plasmid to 300 ng of I-SceI expression vector, 500 ng of control plasmid to 500 
ng of I-SceI expression vector, or 400 ng of control plasmid to 600 ng of I-SceI 
expression vector (Table 2.6). Treatment samples were transfected using Lipofectamine 
LTX with PLUS reagent. In treatments containing 600 ng of DNA, 3 µl of transfection 
reagent and 1 µl of PLUS reagent were used. In treatments containing 1000 ng of DNA, 5 
µl of transfection reagent and 1 µl of PLUS reagent were used. After a 30 hour post-
transfection incubation, cells were harvested in 1 ml of 1x DPBS containing 2% FBS and 
then analyzed by a BD FACSCanto II flow cytometer. A minimum of 10000 viable 
events were analysed for each treatment sample.  
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Checking the I-SceI expression vector in HI5c and I9a. 
Experiment 1:  
HI5c and I9a cells were transfected with three different controls and four different 
experimental treatments using Lipofectamine LTX with PLUS reagent (Life 
Technologies). Cells only, 600 ng of gWIZ-GFP (Genlantis) only, and 600 ng of I-SceI 
expression vector only were the three controls used. Experimental treatments consisted of 
either 600 ng of I-SceI expression vector or 1000 ng of I-SceI expression vector using 
either 3 µl or 5 µl of transfection reagent. Treatments were done as single replicates and 
can be seen in Table 2.7. Cells were harvested 24 hours later in 1 ml of 1x DPBS. The 
centrifugation conditions during harvest were 4ºC, 2000 rpm for 5 minutes. All treatment 
samples underwent FACS analysis. 
  
Experiment 2: 
The control treatments used for this experiment were: 600 ng of pZP500 only, 600 ng of 
pDsRed-Express2-N1 (Clontech) only, and 600 ng of gWIZ-GFP (Genlantis) only (Table 
2.8). There were four control treatments each containing 500 ng of one of four different I-
SceI expression vector stocks and 100 ng of pDsRed-Express2-N1 (Clontech) as a 
transfection control (Table 2.8).  Cells were transfected using 3 µl of Lipofectamine LTX 
(Life Technologies) with 1 µl of PLUS reagent (Life Technologies) in all treatments. 
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Treatments were done as single replicates. Cells were harvested 30 hours later in 500 µl 
of 1x DPBS containing 2% FBS and analysed by flow cytometer.  
 
 
Determining the effect of anti-Ku, anti-DNA-PKCS, anti-PARP-1 antibodies on HR and 
NHEJ levels in HI5c and I9a cells.  
Experiment 1: 
Cells were grown and split into 24-well plates 24 hours prior to transfection. 
Transfections were done using Lipofectamine LTX with Plus Reagent (Life 
Technologies). Control treatments for the experiment included: cells only, 400 ng of 
pDsRed-Express2-N1 (Clontech), 600 ng of I-SceI expression vector, and one using both 
400 ng of pDsRed-Express2-N1 (Clontech) and 600 ng of I-SceI expression vector (Table 
2.9). In experimental treatments where antibodies were delivered simultaneously with the 
plasmids, 400 ng of pDsRed-Express2-N1 (Clontech) and 600 ng of I-SceI expression 
vector were used (Table 2.9). Two amounts of each antibody were used, 2.5 µg and 5.0 
µg (Table 2.9). The antibodies tested were mouse monoclonal antibodies to Ku70 and 
mouse monoclonal antibodies to DNA-PKCS. Cells were harvested in 1 ml of 1x DPBS 
and analysed on the flow cytometer. The centrifugation conditions during harvest were 
4ºC, 2000 rpm for 5 minutes.  
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Experiment 2: 
Cells were grown and split one day prior to transfection into 24-well plates. Transfections 
were done using Lipofectamine LTX with Plus Reagent (Life Technologies). 600 ng of a 
control plasmid (pZP500), gWIZ-GFP (Genlantis), and pDsRed-Express2-N1 (Clontech) 
were each used as controls (Table 2.10). Another control containing both 700 ng of I-SceI 
expression vector and 100 ng of pDsRed-Express2-N1 (Clontech) was also used (Table 
2.10). In experimental treatments where antibodies were delivered simultaneously with 
the plasmids, 700 ng of I-SceI expression vector and 100 ng of pDsRed-Express2-N1 
(Clontech) were used (Table 2.10). Each of the following antibodies were tested: mouse 
monoclonal anti-6X His tag antibody (abcam), mouse monoclonal antibodies to Ku70, 
mouse monoclonal antibodies to DNA-PKCS, and mouse monoclonal antibodies to 
PARP-1 (Table 2.10). The concentrations of antibodies applied were 2.5 µg and 5.0 µg 
(Table 2.10). One additional treatment group included the use of both Ku70 and DNA-
PKCS antibodies, at two concentrations of 1.25 µg each and 2.5 µg each (Table 2.10). In 
treatments containing 600 ng of DNA, 3 µl of transfection reagent and 1 µl of PLUS 
reagent were used. In treatments containing 800 ng of DNA, 3.5 µl of transfection 
reagent and 1 µl of PLUS reagent were used. Cells were harvested 30 hrs after 
transfection in 700 µl of 2% FBS 1x DPBS and analysed on the flow cytometer. A BD 
FACSCanto II flow cytometer was used for FACS analysis. For each sample at least 
20000 cells were analysed. 
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Table 2.1: Treatments for comparing Lipofectamine 2000 (Life Technologies) and 
Chariot (Active Motif) as transfection reagents in HEK293. The treatments also 
worked to observe how transfecting anti-GFP antibodies in conjunction with gWIZ-GFP 
(Genlantis) affect GFP fluorescence. 
No. Treatment Delivery Method gWIZ-
GFP 
(ng) 
pDsRed-
Express2-
N1 (ng) 
pZP500 
(ng) 
Anti-
GFP 
(µg) 
1 pZP500 Lipofectamine 2000 --------- --------- 300 ------ 
2 gWIZ-GFP, pDsRed-
Express2-N1 
Lipofectamine 2000 300 300 --------- ------ 
3 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Lipofectamine 2000 300 300 --------- 2 
4 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Lipofectamine 2000 300 300 --------- 4 
5 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Lipofectamine 2000 300 300 --------- 6 
6 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Lipofectamine 
2000/Chariot 
300 300 --------- 3 
7 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Chariot 300 300 --------- 3 
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Table 2.2: Treatments for comparing Lipofectamine 2000 (Life Technologies) and 
Chariot (Active Motif) as transfection reagents in HEK293. 
No. Treatment Delivery Method gWIZ-
GFP 
(ng) 
pDsRed-
Express2
-N1 (ng) 
pZP500 
(ng) 
Anti-
GFP 
(µg) 
1 Cells Only Lipofectamine 2000 ----------- ----------- ---------- -------- 
2 Cells Only Chariot ----------- ----------- ---------- -------- 
3 gWIZ-GFP, pDsRed-
Express2-N1 
Lipofectamine 2000 300 300 ---------- -------- 
4 gWIZ-GFP, pDsRed-
Express2-N1 
Chariot 300 300 ---------- -------- 
5 pZP500 Lipofectamine 2000 ----------- ----------- 300 -------- 
6 pZP500 Chariot ----------- ----------- 300 -------- 
7 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Lipofectamine 2000 300 300 ---------- 1 
8 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Chariot 300 300 ---------- 1 
9 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Chariot 300 300 ---------- 2 
10 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Chariot 300 300 ---------- 4 
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Table 2.3: Treatments in Experiment 1 for determining the success of anti-GFP 
antibody delivery via Lipofectamine 2000 (Life Technologies) through observations 
of GFP fluorescence changes. 
No. Treatment pZP500 
(ng) 
pDsRed-
Express2-N1 
(ng) 
gWIZ-GFP 
(ng) 
Anti-GFP 
(µg) 
1 Cells Only ---------- ---------- ---------- ---------- 
2 pZP500 300 ---------- ---------- ---------- 
3 pDsRed-Express2-N1 ---------- 300 ---------- ---------- 
4 pDsRed-Express2-N1, 
gWIZ-GFP 
---------- 300 300 ---------- 
5 Anti-GFP Antibody – 1 µg ---------- 300 300 1 
6 Anti-GFP Antibody – 2 µg ---------- 300 300 2 
7 Anti-GFP Antibody – 5 µg ---------- 300 300 5 
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Table 2.4: Treatments in Experiment 2 and 3 for determining the success of anti-
GFP antibody delivery via Lipofectamine 2000 (Life Technologies) through 
observations of GFP fluorescence changes. 
No. Treatment Delivery 
Method 
pZP500 
(ng) 
pDsRed-
Express2
-N1 (ng) 
gWIZ-
GFP 
(ng) 
Anti-
GFP (µg) 
1 pZP500 Lipofectamine 
2000 
300 ---------- ---------- ---------- 
2 pDsRed-Express2-N1 Lipofectamine 
2000 
---------- 300 ---------- ---------- 
3 gWIZ-GFP Lipofectamine 
2000 
---------- ---------- 300 ---------- 
4 pDsRed-Express2-N1 
, gWIZ-GFP 
Lipofectamine 
2000 
---------- 300 300 ---------- 
5 GFP Antibody – 1 µg Lipofectamine 
2000 
---------- 300 300 1 
6 GFP Antibody – 2 µg Lipofectamine 
2000 
---------- 300 300 2 
7 GFP Antibody – 5 µg Lipofectamine 
2000 
---------- 300 300 5 
8 GFP Antibody – 5 µg 
NO TR 
None ---------- ---------- ---------- 5 
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Table 2.5: Treatments for determining the optimal incubation time between 
transfection and harvest in HI5c and I9a. All treatments were transfected with 
TranSIT LT1 (Mirus) and then harvested at a 24 hour, 48 hour, or 72 hour post-
transfection time point. 
No. Treatment pZP500 or 
pDsRed-
Express2-
N1(ng) 
pI-SceI 
or gWIZ-
GFP(ng) 
TR (µl) Time btwn 
Transfection & 
Harvest (hrs) 
1 pZP500 600 ------------ 1.8 24/48/72 
2 pDsRed-Express2-N1 600 ------------ 1.8 24/48/72 
3 gWIZ-GFP ------------ 600 1.8 24/48/72 
4 DsRed:I-SceI LOW 50 550 1.8 24/48/72 
5 DsRed:I-SceI HIGH 100 1100 3.6 24/48/72 
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Table 2.6: Treatments for comparing the transfection success of two potential 
control plasmids -- pDsRed-Express2-N1 (Clontech) and pCMV-Neo-Bam APC 
(Addgene) – in HI5c and I9a. All treatments were transfected with Lipofectamine LTX 
with PLUS Reagent (Invitrogen).  
No. Treatment pCMV-Neo-Bam APC 
or pDsRed-Express2-
N1(ng) 
pI-SceI or 
gWIZ-
GFP(ng) 
1 Cells Only ------------ ------------ 
2 pDsRed-Express2-N1 600 ------------ 
3 pCMV-Neo-Bam APC 600 ------------ 
4 I-SceI expression vector ------------ 600 
5 gWIZ-GFP ------------ 600 
6 pCMV-Neo-Bam APC + I-SceI 
expression vector 300:300 
300 300 
7 pCMV-Neo-Bam APC + I-SceI 
expression vector 500:500 
500 500 
8 pCMV-Neo-Bam APC + I-SceI 
expression vector 400:600 
400 600 
9 pCMV-Neo-Bam APC + I-SceI 
expression vector 300:300 
300 300 
10 pCMV-Neo-Bam APC + I-SceI 
expression vector 500:500 
500 500 
11 pCMV-Neo-Bam APC + I-SceI 
expression vector 400:600 
400 600 
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Table 2.7: Treatments in Experiment 1 to check the I-SceI expression vector in HI5c 
and I9a. All treatments were transfected with Lipofectamine LTX with PLUS Reagent 
(Invitrogen). 
No. Treatment gWIZ-GFP (ng) pI-SceI (ng) TR (µl) 
1 Cells Only ------------ ------------ 3 
2 gWIZ-GFP 600 ------------ 3 
3 I-SceI expression vector - 600ng ------------ 600 3 
4 I-SceI expression vector - 1000ng ------------ 1000 3 
5 I-SceI expression vector - 600ng ------------ 600 5 
6 I-SceI expression vector - 1000ng ------------ 1000 5 
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Table 2.8: Treatments in Experiment 2 to check the I-SceI expression vector in 
HI5c. All treatments were transfected with Lipofectamine LTX with PLUS Reagent 
(Invitrogen). 
No. Treatment pZP500 (ng) pDsRed-
Express2-N1 
(ng) 
gWIZ-GFP 
or pI-SceI 
(ng) 
1 pZP500 600 ------------ ------------ 
2 pDsRed-Express2-N1 ------------ 600 ------------ 
3 gWIZ-GFP ------------ ------------ 600 
4 I-SceI expression vector A ------------ 100 500 
5 I-SceI expression vector B ------------ 100 500 
6 I-SceI expression vector C ------------ 100 500 
7 I-SceI expression vector D ------------ 100 500 
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Table 2.9: Treatments in Experiment 1 for examining the effect of anti-Ku and anti-
DNA-PKCS antibodies on HR and NHEJ levels in HI5c and I9a cells. The transfection 
reagent used for all treatments was Lipofectamine LTX with PLUS Reagent (Invitrogen). 
 
No. Treatment pDsRed-
Express2-N1 (ng) 
pI-SceI 
(ng) 
Anti-
GFP (µg) 
1 Cells Only ----------- -------- ------ 
2 pDsRed-Express2-N1 400 -------- ------ 
3 I-SceI expression vector ----------- 600 ------ 
4 pDsRed-Express2-N1 + I-SceI 
expression vector 
400 600 ------ 
5 pDsRed-Express2-N1 + I-SceI 
expression vector + DNA-PK 0.5 µg 
400 600 0.5 
6 pDsRed-Express2-N1 + I-SceI 
expression vector + DNA-PK 1 µg 
400 600 1 
7 pDsRed-Express2-N1 + I-SceI 
expression vector + Ku70 0.5 µg 
400 600 0.5 
8 pDsRed-Express2-N1 + I-SceI 
expression vector + Ku70 1 µg 
400 600 1 
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Table 2.10: Treatments in Experiment 2 for examining the effect of anti-Ku, anti-
DNA-PKCS, anti-PARP-1 antibodies on HR and NHEJ levels in HI5c and I9a cells. 
All treatments were transfected with Lipofectamine LTX with PLUS Reagent 
(Invitrogen). 
No. Treatment pDsRed-
Express2-N1 
(ng) 
pI-SceI or 
gWIZ-GFP 
(ng) 
Anti-GFP 
(µg) 
1 pZP500 600 ---------- ------ 
2 pDsRed_Express2-N1 600 ---------- ------ 
3 gWIZ-GFP ----------- 600 ------ 
4 pDsRed-Express2-N1  + I-SceI 
expression vector 
100 700 ------ 
5 pDsRed-Express2-N1 + I-SceI 
expression vector + Ctr Ab 2.5 µg 
100 700 0.5 
6 pDsRed-Express2-N1 + I-SceI 
expression vector + Ctr Ab 5 µg 
100 700 1 
7 pDsRed-Express2-N1  + I-SceI 
expression vector + Ku70 2.5 µg 
100 700 0.5 
8 pDsRed-Express2-N1  + I-SceI 
expression vector + Ku70 1 µg 
100 700 1 
9 pDsRed-Express2-N1  + I-SceI 
expression vector + DNA-PK 0.5 µg 
100 700 0.5 
10 pDsRed-Express2-N1  + I-SceI 
expression vector + DNA-PK 1 µg 
100 700 1 
11 pDsRed-Express2-N1  + I-SceI 
expression vector + Parp1 0.5 µg 
100 700 0.5 
12 pDsRed-Express2-N1  + I-SceI 
expression vector + Parp1 1 µg 
100 700 1 
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Figure 2.1: HR Reporter Cassette. The HR reporter construct contains two mutated 
copies of the GFP gene under the control of a CMV promoter (PCMV). One copy is 
disrupted by a stuffer sequence (+) and contains a 22 nucleotide deletion (∆22) in 
addition to the insertion of two I-SceI recognition sites in inverted orientation to one 
another. The second copy is truncated and lacks the ATG transcriptional start codon (-
ATG). SA – splice acceptor, SD – splice donor, dark grey shaded semi-circle. 
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Figure 2.2: NHEJ Reporter Cassette. The NHEJ reporter cassette consists of a GFP 
gene containing an intron from the rat Pem1 gene which has been interrupted by an 
adenoviral exon (Ad, light grey crosshatched box) that is flanked by I-SceI recognition 
sites in direct orientation to one another. SA – splice acceptor, SD – splice donor, dark 
grey shaded semi-circle, PCMV – CMV promoter.  
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Figure 2.3: Sample FACS Analysis Gating. Grey lines are representative of FACS 
analysis gating boundaries. Events within the GFP+ gated area were considered to be 
GFP positive events. Events within the DsRed+ gated area were considered to be DsRed 
positive events.  
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Chapter 3: Results 
 
3.1 Delivery of gWIZ-GFP (Genlantis) and Antibodies Against GFP into HEK293 
Cells 
 
Optimal Conditions for the Transfection of gWIZ-GFP (Genlantis) and pDsRed-
Express2-N1 (Clontech). 
Unpublished work done previously in the lab tested the optimal amount of DNA, ratio of 
gWIZ-GFP (Genlantis) to pDsRed-Express2-N1 (Clontech), time between transfection 
and harvest, and cell line to be used were determined. Optimizations had been done in 
two cell lines, MCF7 and HEK293, and harvested at two post-transfection incubation 
time points, 24 hours and 48 hours (Table 3.1). Three different amounts of total DNA – 
300 ng, 600 ng, and 1200 ng – were tested. Each total DNA amount was used in five 
different ratios of gWIZ-GFP (Genlantis) to pDsRed-Express2-N1 (Clontech) -- 1:0, 1:1, 
2:1, 1:2, and 0:1. It was determined the overall highest level of positive fluorescent 
events was in the treatment with HEK293, a 24 hour post-transfection incubation period, 
and 600 ng of total DNA in a ratio of 300 ng gWIZ-GFP (Genlantis) to 300 ng pDsRed-
Express2-N1 (Clontech). As a result, all experiments were done using these conditions. 
 
Two experiments were initially done using the optimized conditions to determine how the 
concurrent introduction of 0.5 µg, 0.75 µg, or 1 µg of anti-GFP antibodies with the 
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gWIZ-GFP (Genlantis) plasmid affects GFP fluorescence. The cells were fixed in ethanol 
and then stored for five weeks prior to FACS analysis. In all these treatments there was 
little to no fluorescence observed including the gWIZ-GFP (Genlantis) only control. 
Ethanol creates large enough perforations in cells for GFP to leak out making it an 
inappropriate method of cell harvest preparation for this project (Palm et al., 1999). Thus, 
in all ensuing experiments, cells were harvested and prepared for FACS analysis without 
using ethanol fixation.  
 
The transfection success of 300 ng of gWIZ-GFP (Genlantis) and 300 ng of pDsRed-
Express2-N1 (Clontech) was also tested individually. There was no fluorescence signal 
detected in cells only and pZP500 only treatments (Figure 3.1). In the gWIZ-GFP 
(Genlantis) only treatment there were several GFP positive fluorescing events detected 
while in the pDsRed-Express2-N1 (Clontech) only treatment there were several DsRed 
positive events (Figure 3.1).  
 
An unexpected observation was the difference in the percentages of viable events 
between the treatments (Figure 3.2). Harvesting samples was initiated at the same time 
for all treatments, however, because not all the treatment samples could be placed in the 
centrifuge at once, cells from Treatments 3 (pDsRed-Express2-N1 (Clontech) only) and 4 
(pZP500 only) were left on the ice for about 45 minutes longer and analysed about 90 
minutes later than those from Treatments 1 (cells only) and 2 (gWIZ-GFP (Genlantis) 
only). The viability percentages from Treatments 3 and 4 were similar and significantly 
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(t-test, P<0.01 in all cases, n = 3) lower than the viability percentages seen in Treatments 
1 and 2. There was no significant difference in viability between Treatments 1 and 2 or 
between Treatments 3 and 4 (Table 3.2). The lengthy time lapse between harvest 
initiation and FACS analysis may have an effect on sample viability. To prevent this 
factor from influencing future results, cells were harvested in smaller batches with one 
batch being harvested and processed in entirety before harvest initiation of the next. 
 
The experiments showed gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 (Clontech) 
could be successfully transfected into HEK293 cells and the fluorescence of expressed 
GFP and DsRed could be successfully detected using flow cytometry. The experiments 
also influenced how future experiments in this project were designed and how cells were 
harvested and processed for FACS analysis. 
 
 
Comparing the utilisation of Lipofectamine 2000 (Life Technologies) and Chariot (Active 
Motif) as transfection reagents in HEK293 for the co-delivery of gWIZ-GFP (Genlantis), 
pDsRed-Express2-N1 (Clontech), and anti-GPF antibody.  
Two different delivery mechanisms were used to introduce gWIZ-GFP (Genlantis), 
pDsRed-Express2-N1 (Clontech), and anti-GPF antibodies into HEK293 cells (Table 
3.3). Lipofectamine 2000 is a routine transfection reagent used in our lab while Chariot 
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was chosen because it is a commercially available cell-penetrating peptide (CPP) capable 
of delivering antibodies into cells.  
 
In treatments containing gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 (Clontech), 
GFP and DsRed positive events were respectively seen in HEK293 cells when 
Lipofectamine 2000 was utilized as the transfection reagent (Figure 3.3a). When 2 µg or 
6 µg of anti-GFP antibodies were introduced along with both plasmids into HEK293 
cells, there was an elevated but not significant change in GFP positive events. However, 
when 4 µg of the antibody was used there was a slight but significant (t-test, P<0.05) 
increase in GFP fluorescent events. No significant differences in data among the antibody 
treatments were identified. When the relative number of GFP events was normalised 
using the fraction of DsRed positive events in each sample, there were no significant 
differences in the relative amount of GFP events between the control and antibody 
treatments (Figure 3.4a). The level of GFP positive events after normalisation does 
however appear to spike in the presence of 2 µg of antibody. Then as the antibody 
amount increases, they drop back down to the levels of GFP positive events seen in the 
control.  
 
The standard deviation for the viability and GFP positive events in the 2 µg (Treatment 3) 
and 4 µg (Treatment 5) antibody treatments was noticeably large compared to the other 
treatments (Figures 3.3, 3.4 and 3.5). After looking at the data it was apparent that one 
sample per treatment was responsible. The removal of this data point and subsequent 
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analysis reveals there was still no significant change in fluorescence patterns when 2 µg 
of antibody was introduced and there was still a significant (t-test, P<0.05) increase in the 
percentage of GFP positive events when 4 µg of antibody was introduced (Figure 3.3b). 
It is interesting to note, however, that with the removal of the two data points there was 
now a slight but significant (t-test, P<0.05) increase in the percentage of GFP positive 
events in the 6 µg antibody treatment when compared to the no antibody control. There 
were no significant changes in the GFP fluorescence percentages among the antibody 
treatments both before and after the outliers were removed. After normalisation, there 
was no significant differences in the level of GFP positive events between the control and 
the treatment containing 6 µg of anti-GFP antibodies, but there was a significant (t-test, 
P<0.05 in both cases) increase in the GFP positive events when both 2 µg and 4 µg of 
antibody was present (Figure 3.4b). Similar to when the outliers were present, there was a 
spike in GFP positive events with 2 µg of antibody which then dropped down to control 
levels as the amount increased. Among the antibody treatments, a significant (t-test, 
P<0.05) difference was only seen between the 2 µg and 6 µg treatments.   
 
The percentage of DsRed positive events displayed the same pattern both before and after 
the removal of the outlier data points (Figures 3.3 and 3.5). The percentage drops 
significantly (t-test, P<0.001 both before and after outlier removal) in the presence of 2 
µg of anti-GFP antibody; then increases with increasing amounts of antibody. The 
increases between antibody treatments were not significant. Additionally, the percentages 
of DsRed events in the 4 µg and 6 µg treatments did not differ significantly from the no 
antibody control.  
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In the treatment transfected only with Chariot the same observations were not seen. In all 
cases, based on fluorescence, there was no indication that either gWIZ-GFP (Genlantis) 
or pDsRed-Express2-N1 (Clontech) was transfected into and expressed in HEK293 cells 
(Figure 3.3 and 3.4). These findings were supported by a second experiment. It compared 
Lipofectamine 2000 and Chariot as transfection reagents for the following treatments in 
HEK293: cells only, 300 ng of control plasmid (pZP500), 300 ng of each gWIZ-GFP 
(Genlantis) and pDsRed-Express2-N1 (Clontech), and 300 ng of each gWIZ-GFP 
(Genlantis) and pDsRed-Express2-N1 (Clontech) in addition to 1 µg of anti-GFP 
antibodies (Supplementary Table 3.1). Two additional treatments for Chariot (Active 
Motif) contained 300 ng of each gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 
(Clontech) as well as either 2 µg or 4 µg of anti-GFP antibodies. GFP and DsRed positive 
events were only detected in treatments transfected with Lipofectamine 2000 
(Supplementary Figure 3.1 and 3.2).  
 
A final treatment in this experiment used Lipofectamine 2000 to transfect plasmids into 
cells 24 hours prior to harvest and then used Chariot to deliver antibodies three hours 
prior to harvest. This was done to utilize the different transfection reagents in their 
specific delivery role. This allowed for both protocols to be followed while also 
providing enough time for the plasmids to be expressed. Unlike Chariot only treatments, 
in this treatment there were GFP and DsRed positive events present (Figure 3.3 and 3.5). 
Based on fluorescence because there was little difference in GFP positive events when 
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compared to the control, there was also no indication the antibodies were successfully 
delivered both before and after normalisation (Figure 3.4). There was also diminutive 
change in DsRed positive events compared to the no antibody control (Figure 3.3 and 
3.5). Based on the two experiments done, Lipofectamine 2000 was the reagent chosen to 
use for all future experiments in HEK293.  
 
 
Determining the success of anti-GFP antibody delivery via Lipofectamine 2000 through 
observations of GFP fluorescence changes. 
Three experiments were done to test how anti-GFP antibodies affect the percentage of 
GFP positive events in HEK293 cells transfected with Lipofectamine 2000 in the 
presence of gWIZ-GFP (Genlantis) and anti-GFP antibodies (Table 3.4 and 3.5).  For 
each experiment, three different amounts of antibodies were tested: 1 µg, 2 µg, and 5 µg.  
 
In all three experiments the same two general trends were present – the presence of anti-
GFP antibodies was associated with elevated GFP positive events and as the amount of 
antibodies increased the number of DsRed positive events decreased (Figure 3.6). The 
increase in GFP positive events was significant (t-test, P<0.05 in all cases) in all 
experiments when 1 µg of anti-GFP antibodies were present (Table 3.6). When 2 µg of 
antibodies were present the increase was significant (t-test, P<0.01 in both cases) in two 
of the experiments, and when 5 µg was present the increase was only significant (t-test, 
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P<0.01) in one experiment. The decrease in DsRed positive events was significant (t-test, 
P<0.05 for Experiment 1 and P<0.05 for Experiment 2) in two experiments when 5 µg of 
antibodies was present and also significant (t-test, P<0.05 for Experiment 1 and P<0.001 
for Experiment 2) in two experiments when 2 µg of antibodies was present. There were 
no instances when the presence of 1 µg of anti-GFP antibodies was associated with a 
significant decrease in DsRed positive events.  
 
There was also a common trend among all three experiments after normalisation. With 
increasing amounts of anti-GFP antibodies there was an increase in relative amounts of 
GFP positive events (Figure 3.7). The increase in GFP positive events was only 
significant (t-test, P<0.01) in the first experiment between the no antibody control and the 
treatment with 5 µg of antibodies (Table 3.6). The third experiment saw significant (t-
test, P<0.05 for 2 µg and P<0.001 for 5 µg) increases in the relative amounts of GFP 
positive events when both 2 µg and 5 µg of antibodies were present. Consequently there 
was also a significant (t-test, P<0.05) difference between those two treatments. In the 
second experiment, a significant (t-test, P<0.001 for 1 µg and P<0.01 for both 2 µg and 5 
µg) increase was seen for 1 µg, 2 µg, and 5 µg of antibodies when compared to the no 
antibody control. The increase in GFP positive events when compared to the control was 
accompanied by significant (t-test, P<0.01 between 1 µg and 2 µg and P<0.05 between 
Treatments 2 µg and 5 µg) increases as the amount of antibodies increased between 
treatments. There were no significant differences between the viability of the antibody 
treatments and the 0 µg antibody control in all cases (Supplementary Figure 3.3). 
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3.2 Delivery of I-SceI Expression Vector and Antibodies Against DSB DNA Repair 
Factors into HI5c and I9a Cells 
 
The transfection success of Lipofectamine 2000, Lipofectamine LTX with PLUS Reagent, 
and TranSIT LT1 in HI5c and I9a. 
Using three different experiments, three transfection reagents were used to try to 
successfully transfect the HR and NHEJ reporter cassette containing cell lines, 
respectively HI5c and I9a, with the I-SceI expression vector.  
 
The first experiment used the transfection reagent Lipofectamine 2000 to simultaneously 
introduce 300 ng of pDsRed-Express2-N1 (Clontech) with 300 ng, 600 ng, or 1200 ng of 
I-SceI expression vector into the HI5c cell line. Low levels of GFP positive events were 
detected in the gWIZ-GFP (Genlantis) only treatment and negligible amounts were 
detected in treatments containing the I-SceI expression vector both before and after 
normalisation when compared to the controls (Figure 3.8 and 3.9, Supplementary Figure 
3.4). Because there were GFP positive events present in the pDsRed-Express2-N1 
(Clontech) control, this treatment was used as the baseline to compare to the treatments 
containing either gWIZ-GFP (Genlantis) or I-SceI expression vector (Figure 3.8). DsRed 
expression was detected in all treatments where pDsRed-Express2-N1 (Clontech) was 
present, however, there was also some expression detected in the gWIZ-GFP (Genlantis) 
control (Figure 3.8). Interestingly, as the amount of I-SceI expression vector increased so 
did the percentage of DsRed positive events when compared to the pDsRed-Express2-N1 
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(Clontech) control even though they all contained 300 ng of the DsRed encoding plasmid. 
The increase was significant (t-test, P<0.05 for 300 ng of I-SceI expression vector and 
P<0.01 for 600 ng and 1200 ng of I-SceI expression vector) when each experimental 
treatment containing I-SceI expression vector was compared to the pDsRed-Express2-N1 
(Clontech) control and also significant (t-test, P<0.05 in all cases) when the treatments 
with increasing I-SceI expression vector were compared to each other.  
 
In a later trial experiment Lipofectamine 2000 was utilized to introduce either 300 ng, 
600 ng, or 1200 ng of pDsRed-Express2-N1 (Clontech) or 300 ng, 600 ng, or 1200 ng of 
gWIZ-GFP (Genlantis) into HI5c and I9a. This experiment also showed very low 
percentages of GFP and DsRed positive cells when Lipofectamine 2000 was used as a 
transfection reagent (Supplementary Figure 3.5 and 3.6). Also noticeable, overall the 
transfection rate appeared to be lower in I9a when transfected with the same treatments as 
HI5c.    
 
The final experiment compared the success of Lipofectamine LTX with PLUS Reagent 
and TranSIT LT1 as transfection reagents for the HI5c and I9a cell lines. Both 
transfection reagents were used to deliver the following treatments into each cell line: 
cells only, 500 ng of pDsRed-Express2-N1 (Clontech), and 500 ng of both pDsRed-
Express2-N1 (Clontech) and I-SceI expression vector. Similar to the first experiment, 
negligible amounts of GFP positive events were detected in treatments containing the I-
SceI expression vector both before and after normalisation when compared to the controls 
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(Figure 3.10, Supplementary Figure 3.7). DsRed positive events were prevalent in HI5c 
and I9a when either transfection reagent was used (Figure 3.10). DsRed events were 
significantly (t-test, P<0.01 in HI5c and P<0.05 in I9a) higher when Lipofectamine LTX 
with PLUS reagent was used for pDsRed-Express2-N1 (Clontech) only controls and 
similar to TranSIT LT1 transfected cells when the treatment also included the I-SceI 
expression vector. The consistency of transfection overall was better within a treatment 
when TranSIT LT1 was used. Like the second experiment, the overall transfection rate 
was lower in the I9a cell line when transfected with the same treatments as the HI5c cell 
line.   
 
Despite the low transfection rates observed with all transfection reagents tested, because 
the lowest were seen with Lipofectamine 2000 transfection rates it was not used in further 
experiments. Lipofectamine LTX with PLUS reagent and TranSIT LT1 were used for all 
future transfections.  
 
 
Determining the optimal incubation time between transfection and harvest in HI5c and 
I9a. 
Three post-transfection harvest time points – 24 hours, 48 hours, and 72 hours -- were 
investigated based on the work done in Mao et al. (2008). The experiment utilized a low, 
50 ng of pDsRed-Express2-N1 (Clontech) and 550 ng of I-SceI expression vector, and 
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high, 100 ng of pDsRed-Express2-N1 (Clontech) and 1100 ng of I-SceI expression 
vector, amount of plasmid in the experimental treatments. 
 
In all cases the controls were as expected. There was no fluorescence detected in the 
pZP500 control, there was only GFP positive events observed in the gWIZ-GFP 
(Genlantis) control, and there were only DsRed positive events in the pDsRed-Express2-
N1 (Clontech) control (Figure 3.11, Table 3.7, Supplementary Figure 3.8). Similar to 
other experiments, despite using 600 ng of plasmid for all controls the percentage of GFP 
positive events was higher than the percentage of DsRed positive events.   
 
In the HI5c cell line, the percentage of GFP positive events in the gWIZ-GFP (Genlantis) 
control decreased as the length of the harvest time point increased (Figure 3.11, Table 
3.7, Supplementary Figure 3.8). This was significant (t-test, P<0.05 in both cases) 
between the 72 hour time point and the others but not between the 24 hour and 48 hour 
time points.  The percentage of DsRed positive events was highest at 48 hours but only 
significantly (t-test, P<0.05 in the pDsRed-Express2-N1 (Clontech) control, P<0.01 in 
the high experimental treatment, and P<0.001 in the low experimental treatment) when 
compared to the 72 hour time point (Figure 3.11, Table 3.7, Supplementary Figure 3.8). 
The levels were similar between the 24 and 72 hour time points in the experimental 
treatments. Overall the percentage of positive fluorescent events was low ranging from 
0.13% to 1.17%.  
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In I9a the percentage of GFP positive events in the GFP control was the lowest at the 48 
hour post-transfection time point, however, there was no significant difference between 
any of the time points (Figure 3.12, Table 3.8, Supplementary Figure 3.9). The 
percentage of DsRed positive events was the highest at the 72 hours but only significantly 
(t-test, P<0.05 in both cases) higher when compared to the 24 hour time point 
experimental treatments (Figure 3.12, Table 3.8, Supplementary Figure 3.9). Similar to 
HI5c the overall percentage of positive fluorescent events was low ranging from 0.15% to 
1.37%. 
 
As in previous experiments, there were negligible amounts of GFP positive events 
observed in all treatments containing the I-SceI expression vector both before and after 
normalisation (Figure 3.11, 3.12, and 3.13, Table 3.7 and 3.8).  
 
With consideration for viability, there was no clear optimal time point. There was 
variation among treatments within time points, as well as variation between time points 
(Figure 3.14). In the HI5c cell line, a minimum of 20000 events were analysed from each 
sample with the exception of two at the 24 hour time point -- one in the low experimental 
treatment (15033 events were analysed) and another from the high experimental 
treatment (10882 events were analysed). Within the I9a treatments there were several 
samples that did not reach the minimum of 20000 events (Supplementary Figure 3.10). In 
addition, there were only two samples instead of three in Treatments 1 and 4 at the I9a 24 
hour time point. 
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Because the values for all positive fluorescent events were so low it was difficult to draw 
any definitive conclusion. Ultimately the best time point was determined based only on 
the gWIZ-GFP (Genlantis) control. This was largely because it had higher percentages of 
detected events when compared to any of the treatments containing pDsRed-Express2-N1 
(Clontech). In addition, like gWIZ-GFP (Genlantis) the I-SceI expression vector 
expresses GFP. As a result, depending on flow cytometer availability all future 
experiments used either a 24 or 30 hour post-transfection time point. 
  
 
Comparing the transfection success of two potential control plasmids -- pDsRed-
Express2-N1 (Clontech) and pCMV-Neo-Bam APC (Addgene) – in HI5c and I9a.  
Two different plasmids were tested as transfection controls using 3 different ratios of 
control plasmid to I-SceI expression vector: 300:300, 500:500, and 400:600 (Table 3.9). 
The ratios were chosen based on preliminary work done with pDsRed-Express2-N1 
(Clontech), pCMV-Neo-Bam APC (Addgene), and the I-SceI expression vector (data not 
shown). 
 
In their respective treatments, the percentage of DsRed positive events was higher than 
the percentage of APC positive events (Figure 3.16). APC positive events were low in all 
pCMV-Neo-Bam APC (Addgene)-containing treatments and only slightly higher than the 
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cells only control. In addition, there were APC positive events in pDsRed-Express2-N1 
(Clontech) treatments and, to a lesser extent, DsRed positive events in pCMV-Neo-Bam 
APC (Addgene) treatments. This is because DsRed and APC emission spectrums overlap. 
As a result there is some degree of backflow into the others detection channel. Based on 
the results of this experiment, pDsRed-Express2-N1 (Clontech) was retained as the 
transfection control.    
 
GFP positive events were detected in the gWIZ-GFP (Genlantis) control, however, there 
was negligible GFP fluorescence detected in any of the treatments containing the I-SceI 
expression vector (Figure 3.17).  
 
 
Checking the I-SceI expression vector in HI5c and I9a. 
In support of earlier work, two final experiments were done to check the functionality of 
the I-SceI expression vector.   
 
In the first, experimental treatments consisted of either 600 ng or 1000 ng of I-SceI 
expression vector and either 3 µl or 5 µl of the transfection reagent Lipofectamine LTX 
with PLUS reagent (Table 3.10). In both cell lines there was GFP fluorescence in the 
gWIZ-GFP (Genlantis) control and no fluorescence in the cells only control (Figure 
3.18). However despite the distinct fluorescence detected in the gWIZ-GFP (Genlantis) 
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control, there were very low levels (less than 0.5%) of GFP positive events in I9a and 
none in HI5c when only the I-SceI expression vector was present. The viability 
percentages in each treatment were variable and in general low (HI5c: 30-90%; I9a: 20-
50%) (Supplementary Figure 3.11). Only one-third of samples analysed met the 10000 
events minimum (Supplementary Figure 3.12).  
 
In the final experiment, all four stocks of I-SceI expression vector were tested in HI5c. 
Again GFP fluorescence was seen in samples transfected with gWIZ-GFP (Genlantis) 
(Figure 3.19). Also DsRed fluorescence was seen in both the control and experimental 
treatments transfected with DsRed. As seen previously, GFP fluorescence was not seen in 
samples transfected with any of the I-SceI expression vector stocks. Viability was also 
relatively low ranging from about 50-70% (Supplementary Figure 3.13).  
 
 
Determining the effect of anti-Ku, anti-DNA-PKCS, anti-PARP-1 antibodies on HR and 
NHEJ levels in HI5c and I9a cells.  
Despite the lack of success with the I-SceI expression vector, an experiment was done 
using the vector and two different amounts of antibodies against Ku70 and DNA-PKCS 
(Table 3.11). In the HI5c cell line, although there was a trend of decreasing GFP positive 
events with increasing amounts of anti-Ku70 and anti-DNA-PKCS antibodies (Figure 
3.20), the decrease was only significant (t-test, P<0.01 and P<0.05 respectively) between 
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the 2.5 µg and 5 µg anti-Ku70 treatments and between the 2.5 µg anti-DNA-PKCS and 
anti-Ku70 treatments. After normalisation none of the antibody treatments differed 
significantly from one another (Figure 3.21). There was also no significant difference 
between the no antibody control and the antibody treatments both before and after 
normalisation (Figure 3.20 and 3.21). In the I9a cell line there was negligible to no GFP 
positive events in all eight treatments both before and after normalisation (Figure 3.20 
and 3.21).  
 
There were DsRed positive events in the pDsRed-Express2-N1 (Clontech) control as well 
as in the experimental treatments where it acted as a transfection control (Figure 3.20). 
The percentages of viable events were in general lower for I9a treatments (50-65%) in 
comparison to those in HI5c (70-85%) (Supplementary Figure 3.14). Also while all the 
HI5c samples consistently had 10000 FACS analysed events, there were five samples 
among the I9a treatments that did not reach the 10000 minimum – two in the Treatment 2 
(6696 and 6882 events), one in Treatment 4 (5487 events), one in Treatment 7 (5735 
events), and one in Treatment 8 (5518 events).  
 
The concerns with this experiment were the low number of positive fluorescent events, 
the larger margins of error in some treatments, the lower percentages of viability, and 
unexpected results in some of the controls. In the HI5c pDsRed-Express2-N1 (Clontech) 
control there should be no GFP expression because there was no plasmid present that 
encodes GFP (Figure 3.20).  
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In a second experiment, three additional antibody treatments – antibodies against His-
Tag, Parp1, or a combination against Ku70 and DNA-PKCS -- were tested using either 2.5 
µg or 5 ug (Table 3.12). GFP fluorescence was only seen in samples transfected with 
gWIZ-GFP (Genlantis) (data not shown). Despite the presence of DsRed expression from 
the transfection control in experimental treatments, there was no GFP expression detected 
from the I-SceI expression vector hampering any ability to test the effects of the 
antibodies on DSB repair (data not shown). Because of the results seen, all three samples 
were analysed by flow cytometer for only I9a Treatments 1-7. In the remaining I9a and 
HI5c treatments only one sample from each triplicate was analysed.  
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Table 3.1: Treatments for optimizing DNA amounts, the ratio of gWIZ-GFP 
(Genlantis) to pDsRed-Express2-N1 (Clontech), and the post-transfection incubation 
time in HEK293 and MCF7. Each treatment contained a single replicate. TR, 
Transfection Reagent.  
No. Treatment Total 
(ng) 
DNA 
Ratio 
(ng) 
Incubation 
Time 
TR 
(ul) 
1 Cells Only 24 hrs ------- --------- 24hr 4 
2 gWIZ-GFP 300 24 hrs 300 --------- 24hr 4 
3 gWIZ-GFP 600 24 hrs 600 --------- 24hr 4 
4 gWIZ-GFP 1200 24 hrs 1200 --------- 24hr 4 
5 pDsRed-Express2-N1 300 24 hrs 300 --------- 24hr 4 
6 pDsRed-Express2-N1 600 24 hrs 600 --------- 24hr 4 
7 pDsRed-Express2-N1 1200 24 hrs 1200 --------- 24hr 4 
8 gWIZ-GFP: pDsRed-Express2-N1 150:150 24 hrs 300 150:150 24hr 4 
9 gWIZ-GFP: pDsRed-Express2-N1 200:100 24 hrs 300 200:100 24hr 4 
10 gWIZ-GFP: pDsRed-Express2-N1 100:200 24 hrs 300 100:200 24hr 4 
11 gWIZ-GFP: pDsRed-Express2-N1 300:300 24 hrs 600 300:300 24hr 4 
12 gWIZ-GFP: pDsRed-Express2-N1 400:200 24 hrs 600 400:200 24hr 4 
13 gWIZ-GFP: pDsRed-Express2-N1 200:400 24 hrs 600 200:400 24hr 4 
14 gWIZ-GFP: pDsRed-Express2-N1 600:600 24 hrs 1200 600:600 24hr 4 
15 gWIZ-GFP: pDsRed-Express2-N1 800:400 24 hrs 1200 800:400 24hr 4 
16 gWIZ-GFP: pDsRed-Express2-N1 400:800 24 hrs 1200 400:800 24hr 4 
17 Cells Only 48 hrs ------- --------- 48hr 4 
18 gWIZ-GFP 300 48 hrs 300 --------- 48hr 4 
19 gWIZ-GFP 600 48 hrs 600 --------- 48hr 4 
20 gWIZ-GFP 1200 48 hrs 1200 --------- 48hr 4 
21 pDsRed-Express2-N1 300 48 hrs 300 --------- 48hr 4 
22 pDsRed-Express2-N1 600 48 hrs 600 --------- 48hr 4 
23 pDsRed-Express2-N1 1200 48 hrs 1200 --------- 48hr 4 
24 gWIZ-GFP: pDsRed-Express2-N1 150:150 48 hrs 300 150:150 48hr 4 
25 gWIZ-GFP: pDsRed-Express2-N1 200:100 48 hrs 300 200:100 48hr 4 
26 gWIZ-GFP: pDsRed-Express2-N1 100:200 48 hrs 300 100:200 48hr 4 
27 gWIZ-GFP: pDsRed-Express2-N1 300:300 48 hrs 600 300:300 48hr 4 
28 gWIZ-GFP: pDsRed-Express2-N1 400:200 48 hrs 600 400:200 48hr 4 
29 gWIZ-GFP: pDsRed-Express2-N1 200:400 48 hrs 600 200:400 48hr 4 
30 gWIZ-GFP: pDsRed-Express2-N1 600:600 48 hrs 1200 600:600 48hr 4 
31 gWIZ-GFP: pDsRed-Express2-N1 800:400 48 hrs 1200 800:400 48hr 4 
32 gWIZ-GFP: pDsRed-Express2-N1 400:800 48 hrs 1200 400:800 48hr 4 
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Table 3.2: Comparison of the changes in viability between treatments when 
HEK293 cells were transfected with 300 ng of gWIZ-GFP (Genlantis) (Treatment 
2), pDsRed-Express2-N1 (Clontech) (Treatment 3), or pZP500 (Treatment 4) using 
Lipofectamine 2000 (Life Technologies). Treatment 1 was a cells only control. Cells 
were harvested 24 hours after transfection. The time between initiation of harvest and 
FACS analysis was longer for Treatments 3 and 4. Each treatment contained three 
replicates. A minimum of 10000 events were analysed per sample. When the second 
treatment listed showed a significant decrease in viability compared to the first treatment, 
a downward arrow was used to indicate the change. An upward arrow indicated a 
significant increase. Two asterisks represent P<0.01. No significant change between 
treatments is signified by n.s. 
Treatments Compared Significant Increase or Decrease Present 
1 vs. 3 ò/** 
1 vs. 4 ò/** 
2 vs. 3 ò/** 
2 vs. 4 ò/** 
1 vs. 2 n.s. 
3 vs. 4 n.s. 
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Table 3.3: Treatments for comparing Lipofectamine 2000 (Life Technologies) and 
Chariot (Active Motif) as transfection reagents in HEK293. The treatments also 
worked to observe how transfecting anti-GFP antibodies (Santa Cruz Biotechnology) in 
conjunction with gWIZ-GFP (Genlantis) impacts GFP fluorescence. Cells were harvested 
24 hours after transfection. Each treatment contained three replicates. A minimum of 
10000 events were analysed per sample on a BD FACSCanto II flow cytometer. 
No. Treatment Delivery 
Method 
gWIZ-
GFP (ng) 
pDsRed-
Express2-
N1 (ng) 
pZP500 
(ng) 
Anti-
GFP 
(µg) 
1 pZP500 Only Lipofectamine 
2000 
--------- --------- 300 ------ 
2 gWIZ-GFP, pDsRed-
Express2-N1 
Lipofectamine 
2000 
300 300 --------- ------ 
3 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Lipofectamine 
2000 
300 300 --------- 2 
4 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Lipofectamine 
2000 
300 300 --------- 4 
5 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Lipofectamine 
2000 
300 300 --------- 6 
6 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Lipofectamine 
2000/Chariot 
300 300 --------- 3 
7 gWIZ-GFP, pDsRed-
Express2-N1, Ab 
Chariot 300 300 --------- 3 
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Table 3.4: Treatments in Experiment 1 for determining the success of anti-GFP 
antibody delivery via Lipofectamine 2000 (Life Technologies) through observations 
of GFP fluorescence changes. Cells were harvested 24 hours after transfection. Each 
treatment contained three replicates. A minimum of 10000 events were analysed per 
sample on a BD FACSCanto II flow cytometer. 
No. Treatment pZP500 
(ng) 
pDsRed-Express2-
N1 (ng) 
gWIZ-
GFP (ng) 
Anti-
GFP (µg) 
1 Cells Only ---------- ---------- ---------- ---------- 
2 pZP500 300 ---------- ---------- ---------- 
3 pDsRed-Express2-N1 ---------- 300 ---------- ---------- 
4 pDsRed-Express2-N1, 
gWIZ-GFP 
---------- 300 300 ---------- 
5 Anti-GFP Antibody – 1 µg ---------- 300 300 1 
6 Anti-GFP Antibody – 2 µg ---------- 300 300 2 
7 Anti-GFP Antibody – 5 µg ---------- 300 300 5 
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Table 3.5: Treatments in Experiment 2 and 3 for determining the success of anti-
GFP antibody delivery via Lipofectamine 2000 (Life Technologies) through 
observations of GFP fluorescence changes. Cells were harvested 24 hours after 
transfection. Each treatment contained three replicates. A minimum of 20000 events were 
analysed per sample on a BD FACSCanto II flow cytometer. 
No. Treatment Delivery 
Method 
pZP500 
(ng) 
pDsRed-
Express2
-N1 (ng) 
gWIZ-
GFP 
(ng) 
Anti-
GFP (µg) 
1 pZP500 Lipofectamine 
2000 
300 ---------- ---------- ---------- 
2 pDsRed-Express2-N1 Lipofectamine 
2000 
---------- 300 ---------- ---------- 
3 gWIZ-GFP Lipofectamine 
2000 
---------- ---------- 300 ---------- 
4 pDsRed-Express2-N1 
, gWIZ-GFP 
Lipofectamine 
2000 
---------- 300 300 ---------- 
5 GFP Antibody – 1 µg Lipofectamine 
2000 
---------- 300 300 1 
6 GFP Antibody – 2 µg Lipofectamine 
2000 
---------- 300 300 2 
7 GFP Antibody – 5 µg Lipofectamine 
2000 
---------- 300 300 5 
8 GFP Antibody – 5 µg 
NO TR 
None ---------- ---------- ---------- 5 
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Table 3.6: Comparing the changes in positive events between experiments when 
HEK293 cells are transfected with 300 ng of both gWIZ-GFP (Genlantis) and 
pDsRed-Express2-N1 (Clontech) in addition to either 0 µg, 1 µg, 2 µg, or 5 µg of 
anti-GFP antibodies using Lipofectamine 2000 (Life Technologies). Treatment 4 
contained no antibodies; Treatments 5-7 contained 1 µg, 2 µg, and 5 µg of antibodies 
respectively. Treatments 4-7 contained 300 ng of each gWIZ-GFP and pDsRed-
Express2-N1. Each treatment contained three replicates. Cells were harvested 24 hours 
after transfection. For Experiment 1 a minimum of 10000 events were analysed per 
sample on a BD FACSCanto II flow cytometer, for Experiment 2 a minimum of 20000 
viable events were analysed per sample, and for Experiment 3 a minimum of 20000 
events were analysed per sample. When the second treatment listed showed a significant 
change in fluorescent events compared to the first treatment, a downward arrow 
(decrease) or upward arrow (increase) was used to indicate the directional change. A 
P<0.05 is represented by an asterisk. Two asterisks represent P<0.01 and three asterisks 
represent P<0.001. No significant change between treatments is signified by n.s. 
 Experiment 1 Experiment 2 Experiment 3 
Treatments 
Compared 
GFP DsRed GFP/ 
DsRed 
GFP DsRed GFP/ 
DsRed 
GFP DsRed GFP/ 
DsRed 
4 (0 µg) vs. 
5 (1 µg) 
ñ/* n.s. n.s. ñ/* n.s. ñ/*** ñ/* n.s. n.s. 
4 (0 µg) vs. 
6 (2µg) 
ñ/** ò/* n.s. n.s. ò/** ñ/** ñ/** n.s. ñ/* 
4 (0 µg) vs. 
7 (5 µg) 
ñ/** ò/* ñ/** n.s. ò/*** ñ/** n.s. n.s. ñ/*** 
5 (1 µg) vs. 
6 (2 µg) 
n.s. n.s. n.s. ò/** ò/** ñ/* n.s. n.s. n.s. 
5 (1 µg) vs. 
7 (5 µg) 
n.s. n.s. n.s. ò/*** ò/*** ñ/** n.s. n.s. n.s. 
6 (2 µg) vs. 
7 (5 µg) 
n.s. n.s. n.s. n.s. ò/* ñ/** n.s. ò/* ñ/* 
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Table 3.7: Comparing the percentage of positive fluorescing events in HI5c cells at 
three different post-transfection harvest time points: 24, 48, or 72 hours. Cells were 
transfected with: 600 ng of pZP500 (Treatment 1); 600 ng of pDsRed-Express2-N1 
(Clontech) (Treatment 2); 600 ng of gWIZ-GFP (Genlantis) (Treatment 3); and two 
different amounts of the I-SceI expression vector and pDsRed-Express2-N1 (Clontech) 
using TranSIT LT1 (Mirus). Treatment 4 contained 550 ng of I-SceI expression vector 
and 50 ng of pDsRed-Express2-N1 (Clontech) while Treatment 5 contained 1100 ng and 
100 ng respectively. Each treatment contained three replicates. A minimum of 20000 
events were analysed per sample on a BD FACSCanto II flow cytometer. When the 
second treatment listed showed a significant decrease in viability or fluorescent events 
compared to the first treatment, a downward arrow was used to indicate the change. An 
upward arrow indicated a significant increase.  A P<0.05 is represented by an asterisk. 
Two asterisks represent P<0.01 and three asterisks represent P<0.001. No significant 
change between treatments is signified by n.s. 
Treatment Time Points 
Compared 
Viability GFP DsRed   GFP/DsRed 
1 24 hr vs. 48 hr n.s. n.s. n.s. n.s. 
24 hr vs. 72 hr ñ* n.s. n.s. n.s. 
48 hr vs. 72 hr ñ** n.s. n.s. n.s. 
2 24 hr vs. 48 hr n.s. n.s. n.s. n.s. 
24 hr vs. 72 hr n.s. n.s. ò* N/A 
48 hr vs. 72 hr ñ*** n.s. ò* N/A 
3 24 hr vs. 48 hr ò** n.s. n.s. N/A 
24 hr vs. 72 hr n.s. ò* n.s. N/A 
48 hr vs. 72 hr ñ** ò* n.s. N/A 
4 24 hr vs. 48 hr ò** n.s. n.s. n.s. 
24 hr vs. 72 hr n.s. n.s. n.s. n.s. 
48 hr vs. 72 hr ñ** n.s. ò*** n.s. 
5 24 hr vs. 48 hr ò*** n.s. n.s. n.s. 
24 hr vs. 72 hr n.s. n.s. n.s. n.s. 
48 hr vs. 72 hr ñ*** n.s. ò** n.s. 
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Table 3.8: Comparing the percentage of positive fluorescing events in I9a cells at 
three different post-transfection harvest time points: 24, 48, or 72 hours. Cells were 
transfected with: 600 ng of pZP500 (Treatment 1); 600 ng of pDsRed-Express2-N1 
(Clontech) (Treatment 2); 600 ng of gWIZ-GFP (Genlantis) (Treatment 3); and two 
different amounts of the I-SceI expression vector and pDsRed-Express2-N1 (Clontech) 
using TranSIT LT1 (Mirus). Treatment 4 contained 550 ng of I-SceI expression vector 
and 50 ng of pDsRed-Express2-N1 (Clontech) while Treatment 5 contained 1100 ng and 
100 ng respectively. Each treatment contained three replicates. A minimum of 20000 
events were analysed per sample on a BD FACSCanto II flow cytometer. When the 
second treatment listed showed a significant decrease in viability or fluorescent events 
compared to the first treatment, a downward arrow was used to indicate the change. An 
upward arrow indicated a significant increase.  A P<0.05 is represented by an asterisk. 
Two asterisks represent P<0.01 and three asterisks represent P<0.001. A negative sign 
shows there was no significant change between treatments. 
Treatment Time Points 
Compared 
Viability GFP DsRed GFP/DsRed 
1 24 hr vs. 48 hr n.s. n.s. n.s. N/A 
24 hr vs. 72 hr n.s. n.s. n.s. N/A 
48 hr vs. 72 hr n.s. n.s. n.s. N/A 
2 24 hr vs. 48 hr ò* n.s. ò* N/A 
24 hr vs. 72 hr ñ*** n.s. n.s. N/A 
48 hr vs. 72 hr ò* n.s. ñ* N/A 
3 24 hr vs. 48 hr n.s. n.s. n.s. N/A 
24 hr vs. 72 hr ò*** n.s. n.s. N/A 
48 hr vs. 72 hr n.s. n.s. n.s. N/A 
4 24 hr vs. 48 hr n.s. n.s. n.s. n.s. 
24 hr vs. 72 hr ò*** n.s. ñ* n.s. 
48 hr vs. 72 hr ò*** n.s. n.s. n.s. 
5 24 hr vs. 48 hr ñ* n.s. ñ** n.s. 
24 hr vs. 72 hr n.s. n.s. ñ* n.s. 
48 hr vs. 72 hr ò** n.s. n.s. n.s. 
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Table 3.9: Treatments for comparing the transfection success of two potential 
control plasmids -- pDsRed-Express2-N1 (Clontech) and pCMV-Neo-Bam APC 
(Addgene) – in HI5c and I9a. All treatments were transfected with Lipofectamine LTX 
with PLUS Reagent (Invitrogen). Cells were harvested 30 hours after transfection. Each 
treatment contained three replicates and a minimum of 10000 viable events were 
analysed per sample on a BD FACSCanto II flow cytometer. 
No. Treatment pCMV-Neo-Bam 
APC or pDsRed-
Express2-N1(ng) 
pI-SceI or 
gWIZ-GFP (ng) 
1 Cells Only 
 
------------ ----------- 
2 pDsRed-Express2-N1 
 
600 ----------- 
3 pCMV-Neo-Bam APC 
 
600 ----------- 
4 I-SceI expression vector 
 
------------ 600 
5 gWIZ-GFP 
 
------------ 600 
6 pCMV-Neo-Bam APC +  
I-SceI expression vector 300:300 
300 300 
7 pCMV-Neo-Bam APC +  
I-SceI expression vector 500:500 
500 500 
8 pCMV-Neo-Bam APC +  
I-SceI expression vector 400:600 
400 600 
9 pDsRed-Express2-N1 +  
I-SceI expression vector 300:300 
300 300 
10 pDsRed-Express2-N1 +  
I-SceI expression vector 500:500 
500 500 
11 pDsRed-Express2-N1 +  
I-SceI expression vector 400:600 
400 600 
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Table 3.10: Treatments in Experiment 1 checking the I-SceI expression vector in 
HI5c and I9a. All treatments were transfected with Lipofectamine LTX with PLUS 
Reagent (Invitrogen). Cells were harvested 24 hours after transfection. Each treatment 
contained one replicate. A minimum of 10000 events were analysed per sample on a BD 
FACSCanto II flow cytometer. TR, Transfection Reagent.  
No. Treatment gWIZ-GFP 
(ng) 
pI-SceI 
(ng) 
TR (µl) 
1 Cells Only 
 
------------ ------------ 3 
2 gWIZ-GFP 
 
600 ------------ 3 
3 I-SceI expression vector – 600 ng ------------ 600 3 
4 I-SceI expression vector – 1000 ng ------------ 1000 3 
5 I-SceI expression vector – 600 ng ------------ 600 5 
6 I-SceI expression vector – 1000 ng ------------ 1000 5 
   
88 
 
Table 3.11: Treatments in Experiment 1 for determining the effect of anti-Ku and 
anti-DNA-PKCS antibodies on HR and NHEJ levels in HI5c and I9a cells. All 
treatments were transfected with Lipofectamine LTX with PLUS Reagent (Invitrogen). 
Cells were harvested 24 hours after transfection. Each treatment contained three 
replicates. A minimum of 10000 events were analysed per sample on a BD FACSCanto 
II flow cytometer. 
No. Treatment pDsRed-Express2-
N1 (ng) 
pI-SceI 
(ng) 
Anti-
GFP (µg) 
1 Cells Only ---------- ----------- ------------ 
2 pDsRed-Express2-N1 400 ----------- ------------ 
3 I-SceI expression vector ----------- 600 ------------ 
4 pDsRed-Express2-N1 + I-SceI 
expression vector 
400 600 ------------ 
5 pDsRed-Express2-N1 + I-SceI 
expression vector + DNA-PK 0.5 µg 
400 600 0.5 
6 pDsRed-Express2-N1 + I-SceI 
expression vector + DNA-PK 1 µg 
400 600 1 
7 pDsRed-Express2-N1 + I-SceI 
expression vector + Ku70 0.5 µg 
400 600 0.5 
8 pDsRed-Express2-N1 + I-SceI 
expression vector + Ku70 1 µg 
400 600 1 
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Table 3.12: Treatments in Experiment 2 for determining the effect of anti-Ku, anti-
DNA-PKCS, anti-PARP-1 antibodies on HR and NHEJ levels in HI5c and I9a cells. 
All treatments were transfected with Lipofectamine LTX with PLUS Reagent 
(Invitrogen). Cells were harvested 30 hours after transfection. Each treatment contained 
three replicates. A minimum of 20000 events were analysed per sample on a BD 
FACSCanto II flow cytometer. 
No. Treatment pDsRed-
Express2-N1 
(ng) 
pI-SceI or 
gWIZ-GFP 
(ng) 
Anti-
GFP (µg) 
1 pZP500 600 ------------ ------------ 
2 pDsRed-Express2-N1 600 ------------ ------------ 
3 gWIZ-GFP ----------- 600 ------------ 
4 pDsRed-Express2-N1  + I-SceI 
expression vector 
100 700 ------------ 
5 pDsRed-Express2-N1 + I-SceI 
expression vector + Ctr Ab 0.5 µg 
100 700 0.5 
6 pDsRed-Express2-N1 + I-SceI 
expression vector + Ctr Ab 1 µg 
100 700 1 
7 pDsRed-Express2-N1  + I-SceI 
expression vector + Ku70 0.5 µg 
100 700 0.5 
8 pDsRed-Express2-N1  + I-SceI 
expression vector + Ku70 1 µg 
100 700 1 
9 pDsRed-Express2-N1  + I-SceI 
expression vector + DNA-PK 0.5 µg 
100 700 0.5 
10 pDsRed-Express2-N1  + I-SceI 
expression vector + DNA-PK 1 µg 
100 700 1 
11 pDsRed-Express2-N1  + I-SceI 
expression vector + Parp1 0.5 µg 
100 700 0.5 
12 pDsRed-Express2-N1  + I-SceI 
expression vector + Parp1 1 µg 
100 700 1 
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Figure 3.1: The percentage of positive fluorescing events in HEK293 cells 
transfected with 300 ng of gWIZ-GFP (Genlantis) (Treatment 2), pDsRed-Express2-
N1 (Clontech) (Treatment 3), or pZP500 (Treatment 4) using Lipofectamine 2000 
(Life Technologies). Treatment 1 was a cells only control. Cells were harvested 24 hours 
after transfection. Fluorescence was measured using a BD FACSCanto II flow cytometer. 
Each treatment contained three replicates and a minimum of 10000 events were analysed 
per sample. The data are shown as an average percentage of positive events per treatment 
sample with s.d. 
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Figure 3.2: The percentage of viable events in HEK293 cells transfected with 300 ng 
of gWIZ-GFP (Genlantis) (Treatment 2), pDsRed-Express2-N1 (Clontech) 
(Treatment 3), or pZP500 (Treatment 4) using Lipofectamine 2000 (Life 
Technologies). Treatment 1 was a cells only control. Cells were harvested 24 hours after 
transfection. Each treatment contained three replicates. A minimum of 10000 events were 
analysed per sample on a BD FACSCanto II flow cytometer.  The data are shown as an 
average number of viable events per treatment with s.d. A significant change in viability 
from Treatment 1 where P<0.01 is represented by an two asterisks. 
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Figure 3.3: The percentage of positive fluorescing events in HEK293 cells 
transfected with 300 ng of both gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 
(Clontech) in addition to 2 µg, 3 µg, 4 µg, or 6 µg of anti-GFP antibodies (Santa 
Cruz Biotechnology) using either Lipofectamine 2000 (Life Technologies) or Chariot 
(Active Motif). Treatment 1 is a pZP500 only control; Treatment 2 contained no 
antibodies; Treatments 3-5 contained 2 µg, 4 µg, and 6 µg of antibodies respectively; 
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Treatments 6 and 7 both contained 3 µg. Treatments 2-7 also contained 300 ng of each 
gWIZ-GFP and pDsRed-Express2-N1. Treatments 1-5 were transfected with 
Lipofectamine 2000 (Life Technologies), Treatment 6 was transfected with 
Lipofectamine 2000 (Life Technologies) and Chariot (Active Motif), and Treatment 7 
was transfected with only Chariot (Active Motif). Fluorescence was measured using a 
BD FACSCanto II flow cytometer. Cells were harvested 24 hours after transfection. Each 
treatment contained three replicates. A minimum of 10000 events were analysed per 
sample. The data are shown as an average percentage of positive events per treatment 
with s.d. A significant change in the percentage of positive fluorescing events in 
Treatments 3-6 (antibodies present) when compared to Treatment 2 (no antibody control) 
where P<0.05 is represented by an asterisk and three asterisks represent P<0.001. 
A: Percentage of GFP and DsRed positive events per total number of events with 
the outlier data points present in Treatment 3 and 5. 
B: Percentage of GFP and DsRed positive events per total number of events with 
the outlier data points absent in Treatment 3 and 5. 
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Figure 3.4: The relative amount of GFP positive events after normalisation in 
HEK293 cells transfected with 300 ng of both gWIZ-GFP (Genlantis) and pDsRed-
Express2-N1 (Clontech) in addition to 2 µg, 3 µg, 4 µg, or 6 µg of anti-GFP 
antibodies (Santa Cruz Biotechnology) using either Lipofectamine 2000 (Life 
Technologies) or Chariot (Active Motif). Treatment 1 is a pZP500 only control; 
Treatment 2 contained no antibodies; Treatments 3-5 contained 2 µg, 4 µg, and 6 µg of 
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antibodies respectively; Treatments 6 and 7 both contained 3 µg. Treatments 2-7 also 
contained 300 ng of each gWIZ-GFP and pDsRed-Express2-N1. Treatments 1-5 were 
transfected with Lipofectamine 2000 (Life Technologies), Treatment 6 was transfected 
with Lipofectamine 2000 (Life Technologies) and Chariot (Active Motif), and Treatment 
7 was transfected with Chariot (Active Motif). Fluorescence was measured using a BD 
FACSCanto II flow cytometer. Cells were harvested 24 hours after transfection. Each 
treatment contained three replicates and a minimum of 10000 events were analysed per 
sample. The data are shown as an average relative amount of GFP positive events per 
treatment with s.d. A significant change in the relative amount of GFP positive events in 
Treatments 3-6 (antibodies present) when compared to Treatment 2 (no antibody control) 
where P<0.05 is represented by an asterisk. 
A: Percentage of GFP and DsRed positive events per total number of events with 
the outlier data points present in Treatment 3 and 5. 
B: Percentage of GFP and DsRed positive events per total number of events with 
the outlier data points absent in Treatment 3 and 5. 
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Figure 3.5: The percentage of viable events in HEK293 cells transfected with 300 ng 
of both gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 (Clontech) in addition to 2 
µg, 3 µg, 4 µg, or 6 µg of anti-GFP antibodies (Santa Cruz Biotechnology) using 
either Lipofectamine 2000 (Life Technologies) or Chariot (Active Motif). Treatment 
1 is a pZP500 only control; Treatment 2 contained no antibodies; Treatments 3-5 
contained 2 µg, 4 µg, and 6 µg of antibodies respectively; Treatments 6 and 7 both 
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contained 3 µg. Treatments 2-7 also contained 300 ng of each gWIZ-GFP and pDsRed-
Express2-N1. Treatments 1-5 were transfected with Lipofectamine 2000 (Life 
Technologies), Treatment 6 was transfected with Lipofectamine 2000 (Life 
Technologies) and Chariot (Active Motif), and Treatment 7 was transfected with Chariot 
(Active Motif). Cells were harvested 24 hours after transfection. Each treatment 
contained three replicates. A minimum of 10000 events were analysed per sample. The 
data are shown as an average percentage of viable events per treatment with s.d. 
A: Percentage of GFP and DsRed positive events per total number of events with 
the outlier data points present in Treatment 3 and 5. 
B: Percentage of GFP and DsRed positive events per total number of events with 
the outlier data points absent in Treatment 3 and 5. 
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Figure 3.6: The percentage of positive fluorescing events in HEK293 cells 
transfected with 300 ng of both gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 
(Clontech) in addition to either 1 µg, 2 µg, or 5 µg of anti-GFP antibodies using 
Lipofectamine 2000 (Life Technologies). Fluorescence was measured using a BD 
FACSCanto II flow cytometer. Cells were harvested 24 hours after transfection. Each 
treatment contained three replicates. The data are shown as an average percentage of 
positive events per treatment with s.d. A significant change in the percentage of positive 
events in Treatments 5-7 (antibodies present) when compared to Treatment 4 (no 
antibody control) where P<0.05 is represented by an asterisk; two asterisks represents 
P<0.01 and three asterisks represent P<0.001. 
A: Experiment 1 -- A minimum of 10000 total events were analysed per sample. 
Treatment 1 is a cells only control; Treatment 2 is a pZP500 only control; 
Treatment 3 is a pDsRed-Express2-N1 only control; Treatment 4 contained no 
antibodies; Treatments 5-7 contained 1 µg, 2 µg, and 5 µg of antibodies 
respectively. Treatments 4-7 contained 300 ng of each gWIZ-GFP and pDsRed-
Express2-N1. 
B: Experiment 2 -- A minimum of 20000 viable events were analysed per sample. 
Treatment 1 is a pZP500 only control; Treatment 2 is a pDS-Red-Express2-N1 
only control; Treatment 3 is a gWIZ-GFP only control; Treatment 4 contained no 
antibodies; Treatments 5-7 contained 1 µg, 2 µg, and 5 µg of antibodies 
respectively. Treatments 4-7 contained 300 ng of each gWIZ-GFP and pDsRed-
Express2-N1. Treatment 8 was a no transfection reagent control with 5 µg of 
antibodies.  
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C: Experiment 3 -- A minimum of 20000 total events were analysed per sample. 
See Experiment 2 for treatment descriptions. 
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Figure 3.7: The relative amount of GFP positive events after normalisation in 
HEK293 cells transfected with 300 ng of both gWIZ-GFP (Genlantis) and pDsRed-
Express2-N1 (Clontech) in addition to either 1 µg, 2 µg, or 5 µg of anti-GFP 
antibodies using Lipofectamine 2000 (Life Technologies). Fluorescence was measured 
using a BD FACSCanto II flow cytometer. Cells were harvested 24 hours after 
transfection. Each treatment contained three replicates. The data are shown as an average 
relative amount of GFP positive events per treatment with s.d. A significant change in the 
relative amount of GFP positive events in Treatments 5-7 (antibodies present) when 
compared to Treatment 4 (no antibody control) where P<0.05 is represented by an 
asterisk; two asterisks represents P<0.01 and three asterisks represent P<0.001. 
A: Experiment 1 -- A minimum of 10000 total events were analysed per sample. 
No normalisation was done for Treatments 1-3. Treatment 4 contained no 
antibodies and Treatments 5-7 contained 1 µg, 2 µg, and 5 µg of antibodies 
respectively. Treatments 4-7 contained 300 ng of each gWIZ-GFP and pDsRed-
Express2-N1. 
B: Experiment 2 -- A minimum of 20000 viable events were analysed per sample. 
No normalisation was done for Treatments 1-3. Treatment 4 contained no 
antibodies and Treatments 5-7 contained 1 µg, 2 µg, and 5 µg of antibodies 
respectively. Treatments 4-7 contained 300 ng of each gWIZ-GFP and pDsRed-
Express2-N1. Treatment 8 was a no transfection reagent control with 5 µg of 
antibodies.  
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C: Experiment 3 -- A minimum of 20000 total events were analysed per sample. 
See Experiment 2 for treatment descriptions. 
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Figure 3.8: The percentage of fluorescing events in HI5c cells transfected with 300 
ng of pDsRed-Express2-N1 (Clontech) and 300 ng, 600 ng or 1200 ng of I-SceI 
expression vector using Lipofectamine 2000 (Life Technologies). Treatment 1 was a 
cells only control, Treatment 2 was a pDsRed-Express2-N1 (Clontech) control, and 
Treatment 3 was a gWIZ-GFP (Genlantis) control. Treatments 4-6 contained 300 ng of 
pDsRed-Express2-N1 (Clontech) and increasing amounts of I-SceI expression vector – 
300 ng, 600 ng, and 1200 ng. Fluorescence was measured using a BD FACSCanto II flow 
cytometer. Cells were harvested 24 hours after transfection. Each treatment contained 
two replicates and a minimum of 10000 events were analysed per sample. The data are 
shown as an average percentage of positive events per treatment with s.d. A significant 
change in the percentage of GFP positive events in Treatments 3 – 6 when compared to 
Treatment 2 where P<0.05 is represented by an asterisk and two asterisks represents 
P<0.01. 
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Figure 3.9: The relative amount of GFP positive events after normalisation in HI5c 
cells transfected with 300 ng of pDsRed-Express2-N1 (Clontech) and 300 ng, 600 ng 
or 1200 ng of I-SceI expression vector using Lipofectamine 2000 (Life Technologies). 
Treatments 4-6 contained 300 ng of pDsRed-Express2-N1 (Clontech) and increasing 
amounts of I-SceI expression vector – 300 ng, 600 ng, and 1200 ng. Fluorescence was 
measured using a BD FACSCanto II flow cytometer. Cells were harvested 24 hours after 
transfection. Each treatment contained two replicates and a minimum of 10000 events 
were analysed per sample.  The data are shown as the relative amount of GFP positive 
events per treatment with s.d. A significant change in the relative amount of GFP positive 
events in Treatments 5 – 6 when compared to Treatment 4 where P<0.05 is represented 
by an asterisk.  
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Figure 3.10: The percentage of positive fluorescing events in HI5c and I9a cells 
transfected with either 500 ng of pDsRed-Express2-N1 (Clontech) (Treatments 2 
and 5) or 500 ng of both pDSRed-Express2-N1 (Clontech) and I-SceI expression 
vector (Treatments 3 and 6) using Lipofectamine LTX with PLUS Reagent (Life 
Technologies) or TranSIT LT1 (Mirus) (Treatments 1-3 and 4-6 respectively).  
Treatments 1 and 4 were cells only controls. Fluorescence was measured using a BD 
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FACSCanto II flow cytometer. Cells were harvested 24 hours after transfection. Each 
treatment contained three replicates and a minimum of 10000 events were analysed per 
sample. The data are shown as an average percentage of positive events per treatment 
with s.d. A significant change in the percentage of GFP positive events from Treatments 
4 – 6 (transfected with Lipofectamine LTX with PLUS Reagent) respectively when 
compared to Treatment 1-3 (transfected with TranSIT LT1) respectively where P<0.05 is 
represented by an asterisk and two asterisks represents P<0.01. 
A: HI5c 
B: I9a  
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Figure 3.11: Comparing the percentage of positive fluorescing events in HI5c cells at 
three different post-transfection harvest time points: 24, 48, or 72 hours. Cells were 
transfected with: 600 ng of pZP500 (Treatment 1); 600 ng of pDsRed-Express2-N1 
(Clontech) (Treatment 2); 600 ng of gWIZ-GFP (Genlantis) (Treatment 3); and two 
different amounts of the I-SceI expression vector and pDsRed-Express2-N1 (Clontech) 
using TranSIT LT1 (Mirus). Treatment 4 contained 550 ng of I-SceI expression vector 
and 50 ng of pDsRed-Express2-N1 (Clontech) while Treatment 5 contained 1100 ng and 
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100 ng respectively. Fluorescence was measured using a BD FACSCanto II flow 
cytometer. Each treatment contained three replicates and a minimum of 20000 events 
were analysed per sample. The data are shown as an average percentage of positive 
events per treatment with s.d. Significant differences between the different time points 
and treatments are shown in Table 3.7. 
A: Comparison of GFP positive events at three post-transfection time points 
B: Comparison of DsRed positive events at three post-transfection time points 
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Figure 3.12: Comparing the percentage of positive fluorescing events in I9a cells at 
three different post-transfection harvest time points: 24, 48, or 72 hours. Cells were 
transfected with: 600 ng of pZP500 (Treatment 1); 600 ng of pDsRed-Express2-N1 
(Clontech) (Treatment 2); 600 ng of gWIZ-GFP (Genlantis) (Treatment 3); and two 
different amounts of the I-SceI expression vector and pDsRed-Express2-N1 (Clontech) 
using TranSIT LT1 (Mirus). Treatment 4 contained 550 ng of I-SceI expression vector 
and 50 ng of pDsRed-Express2-N1 (Clontech) while Treatment 5 contained 1100 ng and 
100 ng respectively. Fluorescence was measured using a BD FACSCanto II flow 
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cytometer. Each treatment contained three replicates and a minimum of 20000 events 
were analysed per sample. The data are shown as an average percentage of positive 
events per treatment with s.d. Significant differences between the different time points 
and treatments are shown in Table 3.8. 
A: Comparison of GFP positive events at three post-transfection time points 
B: Comparison of DsRed positive events at three post-transfection time points 
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Figure 3.13: Comparing the relative amount of GFP positive events after 
normalisation in I9a cells at three different post-transfection harvest time points: 24, 
48, or 72 hours. In experimental treatments, cells were transfected with two different 
amounts of the I-SceI expression vector and pDsRed-Express2-N1 (Clontech) using 
TranSIT LT1 (Mirus). The low treatment contained 550 ng of I-SceI expression vector 
and 50 ng of pDsRed-Express2-N1 (Clontech) while the high treatment contained 1100 
ng and 100 ng respectively. Fluorescence was measured using a BD FACSCanto II flow 
cytometer. Each treatment contained three replicates and a minimum of 20000 events 
were analysed per sample. The data are shown as an average relative amount of GFP 
positive events per treatment with s.d. Significant differences between the different time 
points and treatments are shown in Table 3.7 and 3.8.
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Figure 3.14: Comparing the percentage of viable events in HI5c and I9a cells at 
three different post-transfection harvest time points: 24, 48, or 72 hours. Cells were 
transfected with: 600 ng of pZP500 (Treatment 1); 600 ng of pDsRed-Express2-N1 
(Clontech) (Treatment 2); 600 ng of gWIZ-GFP (Genlantis) (Treatment 3); and two 
different amounts of the I-SceI expression vector and pDsRed-Express2-N1 (Clontech) 
using TranSIT LT1 (Mirus). Treatment 4 contained 550 ng of I-SceI expression vector 
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and 50 ng of pDsRed-Express2-N1 (Clontech) while Treatment 5 contained 1100 ng and  
100 ng respectively. Each treatment contained three replicates. A minimum of 20000 
events were analysed per sample on a BD FACSCanto II flow cytometer. The data are 
shown as an average percentage of viable events per treatment with s.d. Significant 
differences between the different time points and treatments are shown in Table 3.7 and 
3.8. 
A: HI5c 
B: I9a 
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Figure 3.15: Comparison of APC and DsRed positive fluorescing events in 
experiments comparing pCMV-Neo-Bam APC and pDSRed-Express2-N1 as 
transfection controls. HI5c and I9a cells were transfected with: pDsRed-Express2-N1 
(Clontech); pCMV-Neo-Bam APC (Addgene); I-SceI expression vector; gWIZ-GFP 
(Genlantis); different ratios of pDsRed-Express2-N1 (Clontech) and I-SceI expression 
vector; and different ratios of pCMV-Neo-Bam APC (Addgene) and I-SceI expression 
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vector using Lipofectamine LTX with PLUS Reagent (Life Technologies). Treatment 1 is 
a cells only control, Treatment 2 is a pDsRed-Express2-N1 only control, Treatment 3 is a 
pCMV-Neo-Bam APC only control, Treatment 4 is an I-SceI expression vector only 
control, and Treatment 5 is gWIZ-GFP only control. Treatments 6-8 contain pCMV-Neo-
Bam APC and I-SceI expression vector in ratios of 300 ng:300 ng, 500 ng:500 ng, and 
400 ng:600 ng respectively. Treatments 9-11 contain pDsRed-Express2-N1 and I-SceI 
expression vector in ratios of 300 ng:300 ng, 500 ng:500 ng, and 400 ng:600 ng 
respectively. Fluorescence was measured using a BD FACSCanto II flow cytometer. 
Cells were harvested 30 hours after transfection. Each treatment contained three 
replicates and a minimum of 10000 viable events were analysed per sample. The data are 
shown as an average percentage of positive events per treatment with s.d. 
A: HI5c 
B: I9a 
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Figure 3.16: The percentage of positive fluorescing events in experiments comparing 
pCMV-Neo-Bam APC and pDSRed-Express2-N1 as transfection controls. HI5c and 
I9a cells were transfected with: pDsRed-Express2-N1 (Clontech); pCMV-Neo-Bam APC 
(Addgene); I-SceI expression vector; gWIZ-GFP (Genlantis); different ratios of pDsRed-
Express2-N1 (Clontech) and I-SceI expression vector; and different ratios of pCMV-Neo-
Bam APC (Addgene) and I-SceI expression vector using Lipofectamine LTX with PLUS 
Reagent (Life Technologies). Treatment 1 is a cells only control, Treatment 2 is a 
pDsRed-Express2-N1 only control, Treatment 3 is a pCMV-Neo-Bam APC only control, 
Treatment 4 is an I-SceI expression vector only control, and Treatment 5 is gWIZ-GFP 
only control. Treatments 6-8 contain pCMV-Neo-Bam APC and I-SceI expression vector 
in ratios of 300 ng:300 ng, 500 ng:500 ng, and 400 ng:600 ng respectively. Treatments 9-
11 contain pDsRed-Express2-N1 and I-SceI expression vector in ratios of 300 ng:300 ng, 
500 ng:500 ng, and 400 ng:600 ng respectively. Fluorescence was measured using a BD 
FACSCanto II flow cytometer. Cells were harvested 30 hours after transfection. Each 
treatment contained three replicates and a minimum of 10000 viable events were 
-­‐2	  0	  
2	  4	  
6	  8	  
10	  12	  
14	  16	  
1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   11	  Perce
nt
ag
e	  
of
	  P
os
it
iv
e	  
Ev
en
ts
	  
Treatment	  
GFP	  -­‐	  DsRed	  DsRed	  
D 
119 
 
analysed per sample. The data are shown as an average percentage of positive events per 
treatment with s.d. 
A: HI5c – Comparison of GFP and DsRed positive events gated on a FITC vs. PE 
scatterplot 
B: HI5c – Comparison of GFP and APC positive events gated on a FITC vs. APC 
scatterplot 
C: I9a – Comparison of GFP and DsRed positive events gated on a FITC vs. PE 
scatterplot 
D: I9a – Comparison of GFP and APC positive events gated on a FITC vs. APC 
scatterplot 
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Figure 3.17: The percentage of GFP positive events in HI5c and I9a cells transfected 
with either 600 ng or 1000 ng of I-SceI expression vector and 3 µl or 5 µl of 
Lipofectamine LTX with PLUS Reagent (Life Technologies). Treatment 1 is a cells 
only control and Treatment 2 is a gWIZ-GFP only control. Treatment 3 and 4 were 
transfected with 600 ng and 1000 ng of I-SceI expression vector respectively and 3 µl of 
transfection reagent. Treatment 5 and 6 were transfected with 600 ng and 1000 ng of I-
SceI expression vector respectively and 5 µl of transfection reagent. Fluorescence was 
measured using a BD FACSCanto II flow cytometer. Cells were harvested 24 hours after 
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transfection. A minimum of 10000 events were analysed per sample. There was only one 
sample per treatment so no averages or standard deviations were calculated. 
A: HI5c 
B: I9a 
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Figure 3.18: The percentage of positive fluorescing events in HI5c cells transfected 
with 100 ng of pDsRed-Express2-N1 (Clontech) and 500 ng of one of four I-SceI 
expression vector stocks (Treatments 4-7) using Lipofectamine 2000 (Life 
Technologies). Treatment 1 was a pZP500 control, Treatment 2 was a gWIZ-GFP 
(Genlantis) control, and Treatment 3 was a pDsRed-Express2-N1 (Clontech) control. In 
each control 600 ng of plasmid was used. Fluorescence was measured using a BD 
FACSCanto II flow cytometer. Cells were harvested 30 hours after transfection and a 
minimum of 10000 events were analysed per sample. There was only one sample per 
treatment so no averages or standard deviations were calculated. 
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Figure 3.19: The percentage of positive fluorescing events in HI5c and I9a cells 
transfected with 400 ng of pDsRed-Express2-N, 600 ng of I-SceI expression vector, 
and either 0.5 µg or 1.0 µg of anti-Ku or anti-DNA-PKcs antibodies using 
Lipofectamine LTX with PLUS Reagent (Life Technologies). Treatment 1 is a cells 
only control, Treatment 2 is pDsRed-Express2-N1 only control, Treatment 3 is an I-SceI 
expression vector, and Treatment 4 is a no antibody control. Treatments 5 and 6 
contained 0.5 µg and 1 µg of anti-Ku70 antibodies respectively. Treatments 7 and 8 
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contained 0.5 µg and 1 µg of anti-DNA-PKCS antibodies respectively. Treatments 4-8 
also contained 400 ng of pDsRed-Express2-N1 and 600 ng of I-SceI expression vector. 
Fluorescence was measured using a BD FACSCanto II flow cytometer. Cells were 
harvested 24 hours after transfection. Each treatment contained three replicates and a 
minimum of 10000 events were analysed per sample. The data are shown as an average 
percentage of positive events per treatment with s.d. No significant changes in the 
percentages of positive events were found in Treatments 5-8 (antibodies present) when 
compared to Treatment 4 (no antibody control). 
A: HI5c 
B: I9a 
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Figure 3.20: The relative amount of GFP positive events in HI5c and I9a cells 
transfected with 400 ng of pDsRed-Express2-N1 (Clontech), 600 ng of I-SceI 
expression vector, and either 0.5 µg or 1.0 µg of anti-Ku or anti-DNA-PKcs 
antibodies using Lipofectamine LTX with PLUS Reagent (Life Technologies). No 
normalisation was done for Treatments 1-3. Treatment 4 is a no antibody control, 
Treatments 5 and 6 contained 0.5 µg and 1 µg of anti-Ku70 antibodies respectively, and 
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Treatments 7 and 8 contained 0.5 µg and 1 µg of anti-DNA-PKCS antibodies respectively. 
Treatments 4-8 also contained 400 ng of pDsRed-Express2-N1 and 600 ng of I-SceI 
expression vector. Fluorescence was measured using a BD FACSCanto II flow 
cytometer. Cells were harvested 24 hours after transfection. The data are shown as an 
average relative amount of GFP positive events per treatment with s.d. No significant 
changes in the percentages of positive events in Treatments 5-8 (antibodies present) when 
compared to Treatment 4 (no antibody control) were present. 
A: HI5c 
B: I9a 
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Supplementary Table 3.1: Treatments comparing Lipofectamine 2000 (Life 
Technologies) and Chariot (Active Motif) as transfection reagents in HEK293. Cells 
were harvested 24 hours after transfection. Each treatment contained three replicates. A 
minimum of 10000 events were analysed per sample on a BD FACSCanto II flow 
cytometer. 
No. Treatment Delivery 
Method 
gWIZ-
GFP 
(ng) 
pDsRed-
Express2
-N1 (ng) 
pZP500 
(ng) 
Anti-GFP 
(µg) 
1 Cells Only Lipofectamine 
2000 
--------- --------- --------- --------- 
2 Cells Only Chariot --------- --------- --------- --------- 
3 gWIZ-GFP, pDsRed-
Express2-N1 
Lipofectamine 
2000 
300 300 --------- --------- 
4 gWIZ-GFP, pDsRed-
Express2-N1 
Chariot 300 300 --------- --------- 
5 pZP500 Lipofectamine 
2000 
--------- --------- 300 --------- 
6 pZP500 Chariot --------- --------- 300 --------- 
7 gWIZ-GFP, pDsRed-
Express2-N1, Ab 1 µg 
Lipofectamine 
2000 
300 300 --------- 1 
8 gWIZ-GFP, pDsRed-
Express2-N1, Ab 1 µg 
Chariot 300 300 --------- 1 
9 gWIZ-GFP, pDsRed-
Express2-N1, Ab 2 µg 
Chariot 300 300 --------- 2 
10 gWIZ-GFP, pDsRed-
Express2-N1, Ab 4 µg 
Chariot 300 300 --------- 4 
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Supplementary Figure 3.1: The percentage of positive fluorescing events in HEK293 
cells transfected with 300 ng of both gWIZ-GFP (Genlantis) and pDsRed-Express2-
N1 (Clontech) in addition to 1 µg, 2 µg, or 4 µg of anti-GFP antibodies (Santa Cruz 
Biotechnology). Treatments 1, 3, 5, and 7 were transfected with Lipofectamine 2000 
(Life Technologies). Treatments 2, 4, 6, and 8-10 were transfected with Chariot (Active 
Motif). Treatments 1 and 2 are cells only controls, Treatment 5 and 6 are pZP500 only 
controls, Treatments 3 and 4 are no antibody controls. Treatments 7 and 8 contain 1 µg of 
antibodies, Treatment 9 contains 2 µg of antibodies, and Treatment 10 contains 4 µg of 
antibodies. Treatments 3-4 and 7-10 contain both 300 ng of gWIZ-GFP and 300 ng of 
pDsRed-Express2-N1. Fluorescence was measured using a BD FACSCanto II flow 
cytometer. Cells were harvested 24 hours after transfection. Each treatment contained 
three replicates and a minimum of 10000 events were analysed per sample. The data are 
shown as an average percentage of positive events per treatment with s.d. 
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Supplementary Figure 3.2: The percentage of viable events in HEK293 cells 
transfected with 300ng of both gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 
(Clontech) in addition to 1µg, 2µg, or 4µg of anti-GFP antibodies (Santa Cruz 
Biotechnology) using Lipofectamine 2000 (Life Technologies) or Chariot (Active 
Motif). Treatments 1, 3, 5, and 7 were transfected with Lipofectamine 2000 (Life 
Technologies). Treatments 2, 4, 6, and 8-10 were transfected with Chariot (Active Motif). 
Treatments 1 and 2 are cells only controls, Treatment 5 and 6 are pZP500 only controls, 
Treatments 3 and 4 are no antibody controls. Treatments 7 and 8 contain 1 µg of 
antibodies, Treatment 9 contains 2 µg of antibodies, and Treatment 10 contains 4 µg of 
antibodies. Treatments 3-4 and 7-10 contain both 300 ng of gWIZ-GFP and 300 ng of 
pDsRed-Express2-N1. Cells were harvested 24 hours after transfection. Each treatment 
contained three replicates and a minimum of 10000 events were analysed per sample on a 
BD FACSCanto II flow cytometer. The data are shown as an average percentage of 
viable events per treatment with s.d. 
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Supplementary Figure 3.3: The percentage of viable events in HEK293 cells 
transfected with 300 ng of both gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 
(Clontech) in addition to either 1 µg, 2 µg, or 5 µg of anti-GFP antibodies (Santa 
Cruz Biotechnology) using Lipofectamine 2000 (Life Technologies). Cells were 
harvested 24 hours after transfection. Each treatment contained three replicates and a 
minimum of 10000 events were analysed per sample on a BD FACSCanto II flow 
cytometer. The data are shown as an average percentage of viable events per treatment 
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with s.d. No significant changes in the percentages of viable events were present in 
Treatments 5-7 (antibodies present) when compared to Treatment 4 (no antibody control). 
A: Experiment 1 -- Treatment 1 is a cells only control; Treatment 2 is a pZP500 
only control; Treatment 3 is a pDsRed-Express2-N1 only control; Treatment 4 
contained no antibodies; Treatments 5-7 contained 1 µg, 2 µg, and 5 µg of 
antibodies respectively. Treatments 4-7 contained 300 ng of each gWIZ-GFP and 
pDsRed-Express2-N1. 
B: Experiment 2 -- Treatment 1 is a pZP500 only control; Treatment 2 is a pDS-
Red-Express2-N1 only control; Treatment 3 is a gWIZ-GFP only control; 
Treatment 4 contained no antibodies; Treatments 5-7 contained 1 µg, 2 µg, and 5 
µg of antibodies respectively. Treatments 4-7 contained 300 ng of each gWIZ-
GFP and pDsRed-Express2-N1. Treatment 8 was a no transfection reagent control 
with 5 µg of antibodies.  
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Supplementary Figure 3.4: The percentage of viable events in HI5c cells transfected 
with 300 ng of pDsRed-Express2-N1 (Clontech) and 300 ng, 600 ng or 1200 ng of I-
SceI expression vector using Lipofectamine 2000 (Life Technologies). Treatment 1 
was a cells only control, Treatment 2 was a pDsRed-Express2-N1 (Clontech) only 
control, and Treatment 3 was a gWIZ-GFP (Genlantis) only control. Treatments 4-6 
contained 300 ng of pDsRed-Express2-N1 (Clontech) and increasing amounts of I-SceI 
expression vector – 300 ng, 600 ng, and 1200 ng. Cells were harvested 24 hours after 
transfection. Each treatment contained two replicates. A minimum of 10000 events were 
analysed per sample on a BD FACSCanto II flow cytometer. The data are shown as an 
average percentage of viable events per treatment with s.d. A significant change in the 
percentage of viable events in Treatments 3 – 6 when compared to Treatment 2 where 
P<0.01 is represented by two asterisks. 
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Supplementary Figure 3.5: The percentage of positive fluorescing events in HI5c 
and I9a cells transfected with 300 ng, 600 ng, or 1200 ng of pDsRed-Express2-N1 
(Clontech) (Treatments 2-4 respectively) or gWIZ-GFP (Genlantis) (Treatments 5-7 
respectively) using Lipofectamine 2000 (Life Technologies). Treatment 1 was a cells 
only control. Fluorescence was measured using a BD FACSCanto II flow cytometer. 
Cells were harvested 24 hours after transfection. Each treatment contained two replicates 
and a minimum of 10000 events were analysed per sample. The data are shown as an 
average percentage of fluorescing events per treatment with s.d. 
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Supplementary Figure 3.6: The percentage of viable events in HI5c and I9a cells 
transfected with 300 ng, 600 ng, or 1200 ng of pDsRed-Express2-N1 (Clontech) 
(Treatments 2-4 respectively) or gWIZ-GFP (Genlantis) (Treatments 5-7 
respectively) using Lipofectamine 2000 (Life Technologies). Treatment 1 was a cells 
only control. Cells were harvested 24 hours after transfection. Each treatment contained 
two replicates. A minimum of 10000 events were analysed per sample on a BD 
FACSCanto II flow cytometer. The data are shown as an average percentage of viable 
events per treatment with s.d. 
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Supplementary Figure 3.7: The percentage of viable events in HI5c and I9a cells 
transfected with either 500 ng of pDsRed-Express2-N1 (Clontech) (Treatments 2 
and 5) or 500 ng of both pDSRed-Express2-N1 (Clontech) and I-SceI expression 
vector (Treatments 3 and 6) with PLUS reagent using Lipofectamine LTX with 
PLUS Reagent (Life Technologies) or TranSIT LT1 (Mirus) (Treatments 1-3 and 4-
6 respectively).  Treatments 1 and 4 were cells only controls. Cells were harvested 24 
hours after transfection. Each treatment contained three replicates. A minimum of 10000 
events were analysed per sample on a BD FACSCanto II flow cytometer. The data are 
shown as an average percentage of viable events per treatment with s.d. 
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Supplementary Figure 3.8: The percentage of positive fluorescing events in HI5c 
cells transfected with: pZP500 (Treatment 1); pDsRed-Express2-N1 (Clontech) 
(Treatment 2); gWIZ-GFP (Genlantis) (Treatment 3); and two different amounts of 
the I-SceI expression vector and pDsRed-Express2-N1 (Clontech) using TranSIT 
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LT1 (Mirus). The controls contained 600 ng of plasmid. Treatment 4 contained 550 ng 
of I-SceI expression vector and 50 ng of pDsRed-Express2-N1 (Clontech) while 
Treatment 5 contained 1100 ng of I-SceI expression vector and 100 ng of pDsRed-
Express2-N1 (Clontech). Cells were harvested 24, 48, or 72 hours after transfection. 
Fluorescence was measured using a BD FACSCanto II flow cytometer. Each treatment 
contained three replicates and a minimum of 10000 events were analysed per sample. 
Each treatment contained three replicates. A minimum of 10000 events were analysed per 
sample.  The data are shown as an average percentage of positive events per treatment 
with s.d. 
A: 24 hour post-transfection harvest time point 
B: 48 hour post-transfection harvest time point 
C: 72 hour post-transfection harvest time point 
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Supplementary Figure 3.9: The percentage of positive fluorescing events in I9a cells 
transfected with: pZP500 (Treatment 1); pDsRed-Express2-N1 (Clontech) 
(Treatment 2); gWIZ-GFP (Genlantis) (Treatment 3); and two different amounts of 
the I-SceI expression vector and pDsRed-Express2-N1 (Clontech) using TranSIT 
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LT1 (Mirus). The controls contained 600 ng of plasmid. Treatment 4 contained 550 ng 
of I-SceI expression vector and 50 ng of pDsRed-Express2-N1 (Clontech) while 
Treatment 5 contained 1100 ng of I-SceI expression vector and 100 ng of pDsRed-
Express2-N1 (Clontech). Cells were harvested 24, 48, or 72 hours after transfection. 
Fluorescence was measured using a BD FACSCanto II flow cytometer. Each treatment 
contained three replicates and a minimum of 10000 events were analysed per sample. The 
data are shown as an average percentage of positive events per treatment with s.d. 
A: 24 hour post-transfection harvest time point 
B: 48 hour post-transfection harvest time point 
C: 72 hour post-transfection harvest time point 
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Supplementary Figure 3.10: The number of events analysed by a BD FACSCanto II 
flow cytometer per I9a sample. Samples were transfected with: pZP500 (Treatment 1); 
pDsRed-Express2-N1 (Clontech) (Treatment 2); gWIZ-GFP (Genlantis) (Treatment 3); 
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or two different amounts of the I-SceI expression vector and pDsRed-Express2-N1 
(Clontech) using TranSIT LT1 (Mirus). The controls contained 600 ng of plasmid. 
Treatment 4 contained 550 ng of I-SceI expression vector and 50 ng of pDsRed-
Express2-N1 (Clontech) while Treatment 5 contained 1100 ng of I-SceI expression vector 
and 100 ng of pDsRed-Express2-N1 (Clontech). Each treatment contained three samples. 
Cells were harvested 24, 48, or 72 hours after transfection. Samples with 20000 events 
analysed were those that met the minimum 20000 events requirement. 
A: 24 hour post-transfection harvest time point 
B: 48 hour post-transfection harvest time point 
C: 72 hour post-transfection harvest time point   
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Supplementary Figure 3.11: The percentage of viable events in HI5c and I9a cells 
transfected with 600 ng or 1000 ng of I-SceI expression vector and 3 µl or 5 µl of 
Lipofectamine LTX with PLUS Reagent (Life Technologies). Treatment 1 is a cells 
only control and Treatment 2 is a gWIZ-GFP only control. Treatment 3 and 4 were 
transfected with 600 ng and 1000 ng of I-SceI expression vector respectively and 3 µl of 
transfection reagent. Treatment 5 and 6 were transfected with 600 ng and 1000 ng of I-
SceI expression vector respectively and 5 µl of transfection reagent. Cells were harvested 
24 hours after transfection. A minimum of 10000 events were analysed per sample on a 
BD FACSCanto II flow cytometer. There was only one sample per treatment. 
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A: HI5c 
B: I9a  
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Supplementary Figure 3.12: The number of events analysed by a BD FACSCanto II 
flow cytometer per HI5c and I9a sample. Samples were transfected with 600 ng or 
1000 ng of I-SceI expression vector and 3 µl or 5 µl of Lipofectamine LTX with PLUS 
Reagent (Life Technologies). Treatment 1 is a cells only control and Treatment 2 is a 
gWIZ-GFP only control. Treatment 3 and 4 were transfected with 600 ng and 1000 ng of 
I-SceI expression vector respectively and 3 µl of transfection reagent. Treatment 5 and 6 
were transfected with 600 ng and 1000 ng of I-SceI expression vector respectively and 5 
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µl of transfection reagent. Cells were harvested 24 hours after transfection. There was 
only one sample per treatment. 
A: HI5c 
B: I9a 
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Supplementary Figure 3.13: The percentage of viable events in HI5c cells 
transfected with 100 ng of pDsRed-Express2-N1 (Clontech) and 500 ng of one of 
four I-SceI expression vector stocks (Treatments 4-7) using Lipofectamine 2000 
(Life Technologies). Treatment 1 was a pZP500 control, Treatment 2 was a gWIZ-GFP 
(Genlantis) control, and Treatment 3 was a pDsRed-Express2-N1 (Clontech) control. In 
each control 600 ng of plasmid was used. Cells were harvested 30 hours after 
transfection. A minimum of 10000 events were analysed per sample on a BD FACSCanto 
II flow cytometer. There was only one sample per treatment. 
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Supplementary Figure 3.14: The percentage of viable events in HI5c and I9a cells 
transfected with 400 ng of pDsRed-Express2-N1 (Clontech), 600 ng of I-SceI 
expression vector, and either 0.5 µg or 1.0 µg of anti-Ku or anti-DNA-PKcs 
antibodies using Lipofectamine LTX with PLUS Reagent (Life Technologies). 
Treatment 1 is a cells only control, Treatment 2 is pDsRed-Express2-N1 only control, 
Treatment 3 is an I-SceI expression vector, and Treatment 4 is a no antibody control. 
Treatments 5 and 6 contained 0.5 µg and 1 µg of anti-Ku70 antibodies respectively. 
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Treatments 7 and 8 contained 0.5 µg and 1 µg of anti-DNA-PKCS antibodies respectively. 
Treatments 4-8 also contained 400 ng of pDsRed-Express2-N1 and 600 ng of I-SceI 
expression vector. Fluorescence was measured using a BD FACSCanto II flow 
cytometer. Cells were harvested 24 hours after transfection. Each treatment contained 
three replicates. A minimum of 10000 events were analysed per sample. The data are 
shown as an average percentage of viable events per treatment with s.d. A significant 
change in the percentage of viable events in Treatments 5-8 (antibodies present) when 
compared to Treatment 4 (no antibody control) is represented by an asterisk; two 
asterisks represents P<0.01 and three asterisks represent P<0.001. 
A: HI5c 
B: I9a 
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Chapter 4: Discussion 
 
4.1 Delivery of gWIZ-GFP and Antibodies Against GFP into HEK293 Cells 
 
DSBs are primarily repaired in eukaryotic cells by two different mechanisms – NHEJ or 
HR. In mammalian somatic cells NHEJ is the preferred mechanism for repairing these 
breaks. Because gene targeting utilizes HR repair to alter a defined gene locus, this has 
proven to be a challenge to the advancement of the field and its applications. To address 
this problem, the present study attempted to use antibodies to target key DSB repair 
proteins to shift the balance from NHEJ to HR. The successful introduction of antibodies 
was pertinent to this investigation. In an attempt to demonstrate this, flow cytometry was 
used to assess the simultaneous introduction of gWIZ-GFP (Genlantis) and antibodies 
against GFP into human cells.  
 
The anti-GFP antibody utilized was a mouse monoclonal antibody that binds to amino 
acids 1-238 of GFP, a range representative of the entire protein. It was predicted that the 
binding of the antibody to expressed GFP would interfere with the proteins ability to 
fluoresce. Thus successful introduction and binding could be quantified by a decrease in 
GFP positive events. In reality the opposite effect was seen. In experimental treatments 
where antibodies were present the percentage of GFP positive events was elevated and in 
many cases significantly increased when compared to the no antibody control. Before 
normalisation, the increase seen did not correspond to increasing amounts of plasmid 
(Figure 3.6). However, after normalisation as the amount of antibodies increased from 1 
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µg to 5 µg there was a trend of increasing relative amounts of GFP positive events 
(Figure 3.7). This cannot be attributed to antibodies binding to GFP and enhancing 
fluorescence because a positive event is considered a positive event when it falls within 
the gated region regardless of fluorescence intensity. Interestingly, in conjunction with 
the increase in GFP positive events, there was also a decrease in DsRed positive events 
(Figure 3.6).  
 
Two possible explanations might explain the unexpected observations -- the presence of 
antibodies affects the transfection efficiencies of the plasmids or the presence of 
antibodies affects plasmid expression once entry into the cell has occurred. Given the 
target and source of the antibodies it is unlikely plasmid expression is affected. In 
addition, if expression machinery was being targeted, the effect on the production of the 
fluorescent products from gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 (Clontech) 
would likely be similar. There is a possibility, however, the antibodies may interact with 
the plasmids once they have entered the cell and can alter their expression but again this 
explanation would need to be investigated.  
 
Based on the changes seen in both GFP and DsRed positive events, it is also probable 
that the presence of antibodies may have an effect on the efficiency of transfection -- 
simultaneously encouraging uptake of gWIZ-GFP (Genlantis) and discouraging the 
uptake of pDsRed-Express2-N1 (Clontech). Consequently after taking into consideration 
the decreasing effect the presence of gWIZ-GFP (Genlantis) has on DsRed positive 
events (Figure 3.6), it is also possible that the antibodies may only affect the transfection 
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efficiency of gWIZ-GFP (Genlantis) and that the effect on DsRed positive events is 
directly the result of increased numbers of GFP positive events. The two plasmids 
employ a CMV promoter, however, the promoter in gWIZ-GFP (Genlantis) has been 
modified to increase transcriptional activity. In cells where both plasmids have 
successfully been transfected it is reasonable to assume gWIZ-GFP (Genlantis) would be 
preferentially transcribed resulting in a decrease in DsRed events. Because all antibody 
treatments were done with both plasmids present, it is difficult to know what affect the 
presence antibodies have on the transfection of the plasmids and what affect the plasmids 
have on each other. One way to test this would be to have treatments with consistent 
amounts of either gWIZ-GFP (Genlantis) or pDsRed-Express2-N1 (Clontech) and 
increasing amounts of antibodies. To determine if any outcomes seen are specific to the 
anti-GFP antibodies, a control antibody could be utilized. Regardless of whether the 
antibodies affect the expression or transfection efficiency, if they affect the plasmids 
differently, the reliability of the normalisation method used may need to be considered. 
 
Because transfection efficiencies are not always consistent from reaction to reaction 
despite using similar conditions, normalisation was done to counteract any effect it could 
have on the results collected. This was done using pDsRed-Express2-N1 (Clontech) as a 
transfection control. In experimental treatments where both gWIZ-GFP (Genlantis) and 
pDsRed-Express2-N1 (Clontech) were used in consistent amounts, the number of GFP 
positive events was divided by the number of DsRed positive events. In theory it is 
expected that as the transfection efficiency of a reaction changes, the change would 
subsequently be mirrored similarly in both the number of GFP and DsRed positive 
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events. However, if the plasmids are affected differently by the antibodies or in the case 
that they affect one another, the present normalisation method may not provide a 
complete picture of what is actually happening. This point can be illustrated by 
considering the reciprocal trends of the normalised results from the gWIZ-GFP 
(Genlantis)/anti-GFP antibody experiments with the DsRed positive events (Figure 3.6 
and 3.7). If there is a separate and distinct effect on the number of DsRed positive events, 
using the present method of normalisation the distinct effect on DsRed positive events 
will be reflected in the normalised GFP positive events, potentially masking or altering 
what is actually happening to the number of GFP positive events. Coupled with 
experiments designed to see how increasing amounts of the antibodies impact the number 
of GFP and DsRed positive events, it would also be beneficial to investigate how the 
amount of each plasmid impacts the transfection efficiency or expression of the other.  
 
While the unexpected results did signify detectable changes in fluorescence, they were 
unable to confirm whether antibodies had been successfully introduced into cells. If the 
deviation in the number of positive events is in actuality the result of the antibodies 
interfering with transfection, it is reasonable to assume this is possible regardless of 
successful antibody delivery into cells. It would have been beneficial to harvest cells and 
run western blots on the cell extracts in an attempt to determine if antibodies were in fact 
being successfully delivered. In the event it is found antibodies are not entering the cell, it 
may be necessary to explore other antibody delivery reagents or possibly even introduce 
antibody-encoding plasmids instead of the antibodies directly. 
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4.2 Delivery of I-SceI Expression Vector and Antibodies Against DSB DNA Repair 
Factors into HI5c and I9a Cells 
 
Somatic human cell lines containing reporter cassettes for either NHEJ or HR were 
exploited to examine the consequences antibodies against DSB repair proteins have on 
natural NHEJ and HR repair levels. The cassettes were designed to detect repair events of 
one of the two DSB repair mechanisms following artificially induced DSBs by the 
endonuclease I-SceI. An expression vector that was transfected into the cells along with 
the antibodies encoded the endonuclease responsible. Without the successful transfection 
and expression of the I-SceI expression vector, there can be no detection of NHEJ or HR 
repair events. 
 
In all experiments conducted, despite the successful transfection and expression of the 
control plasmids, gWIZ-GFP (Genlantis) and pDsRed-Express2-N1 (Clontech), there was 
no indication the I-SceI expression vector was effectively transfected and expressed in 
HI5c or I9a (Figure 3.8-13, 3.16-20, Supplementary Figure 3.8 & 3.9). Even in 
experiments where there were low levels of GFP positive events present in treatments 
containing I-SceI expression vector, the levels were similar to background GFP amounts 
seen in the cells only or pDsRed-Express2-N1 (Clontech) controls making it impossible 
to differentiate any GFP positive events produced as a result of HR or NHEJ repair 
(Figure 3.8, 3.16, 3.17, 3.19). There are a few different reasons that may explain why no 
definitive results were observed. One of the major differences between what was used in 
this study and what was done by the authors of the paper originally describing the cell 
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lines, was the different transfection methods employed. The original method of 
transfection utilised the Amaxa Nucleofector System (Mao et al., 2008a). Because our lab 
was not equipped with a Nucleofector device, transfection reagents from Life 
Technologies and Mirus were used. It is difficult to know whether or not this may have 
contributed to our lack of success without having access to the Amaxa Nucleofector 
System for comparison purposes. If future work is to proceed with the cells lines and 
endonuclease expression vector this will be an area that will need to be further explored. 
In addition, to rule out any possibility that the negligible amounts of GFP positive events 
are not the result of defective reporter cassettes or the I-SceI expression vector, further 
sequencing should be done to ensure no mutations exist. 
 
Another factor that may have an impact on the results of the experiments is the link 
between viability and GFP positive events. The possible connection surfaced following 
the experiment in HEK293 where large standard deviations for viability and GFP positive 
events in treatments 3 and 5 were the result of single outliers (Figure 3.3a and 3.5a). For 
most HEK293 experiments the level of viability was fairly consistent, unfortunately, this 
was not always the case for HI5c and I9a. With both cell lines there was a higher degree 
of variability that may have had some influence on the results observed. To help alleviate 
this problem, 2% FBS in DPBS was used to harvest cells instead of just using DPBS. 
Improvements were seen, but not enough to completely eliminate deviations. 
Accordingly, for future work it may be beneficial to only look at the percentage of 
positive fluorescence events in viable cells to eliminate any influence viability may have 
on the percentage of GFP positive events.  
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Although the work done in this study was unable to successfully demonstrate whether or 
not antibodies against DSB repair proteins can cause a shift in the repair balance, other 
studies have. An early study done in vitro, looked at the repair of linearlized plasmid 
DNA in whole cell extract from human cell lines. It found that NHEJ could be inhibited 
by anti-Ku antibodies but in order for the inhibition to effective, DNA-PKCS needed to be 
present (Wang et al., 2003). In the presence of antibodies, Ku still had the capacity to 
bind to DNA ends, indicating the anti-Ku antibodies inhibited the actions of Ku later on 
in the NHEJ repair process. The effect does not appear to be solely restricted to 
mammalian cells. In Xenopus egg extract it was shown that four different anti-Ku 
autoimmune sera had inhibitory effects on NHEJ reactions (Labhart, 1999). The 
inhibitory effect was abolished when the sera was pre-incubated with human Ku. 
Antibodies against DNA-PKCS were also utilised but no observable differences in NHEJ 
were established. A final study was conducted in one-celled mouse embryos. RNA/DNA, 
morpholino, or ssDNA constructs along with other factors were introduced using 
microinjection (Morozov & Wawrousek, 2008). The constructs were designed to insert a 
point mutation in an αβ-crystallin gene within the embryos. When no additional factors 
were present there was no evidence to indicate successful incorporation of the point 
mutation. However, when antibodies against Ku were used in conjunction with the 
ssDNA constructs there were mutational insertions detected. The use of mammalian 
nuclear extract, DNA-PK, or antibodies against rad51 had no effect on the efficiency of 
mutational insertion. 
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Each of the monoclonal antibodies used in this study bind to active domains within the 
targeted proteins. The anti-Ku70 antibody binds to amino acids 506-541 near the C-
terminal arm, a region has been implicated in interactions with both Ku80 and DNA-
PKCS (Gell & Jackson, 1999). The antibody against DNA-PKCS binds to the 1-2713 
amino acid region at the N-terminal. Reviewed entries in the UniProtKB database 
recognize within this range of amino acids a region that binds to kinase interacting 
protein (KIP), a protein believed to be involved in DNA DSB repair (Wu & Lieber, 
1997). The region also contains a leucine-zipper domain that is suspected be involved in 
interactions with C1D, a protein with a strong affinity for DNA (Yavuzer et al., 1998), as 
well as a possible caspase-3 cleavage site (Teraoka et al., 1996). Finally the antibodies 
against PARP-1 target amino acids 764-1014, a region that contains the PARP catalytic 
domain (Rolli et al., 1997; Simonin et al., 1990). All the targets of the antibodies chosen 
are involved to some degree in DNA repair. If antibodies are able to enter the cell and 
bind to the target protein then, in theory and based on previous research, there should be 
some repercussions to DSB DNA repair.  
 
Over the past few decades there have been many studies investigating the relationship 
between HR and NHEJ and how this knowledge can be used to improve current gene 
targeting methods (Kass & Jasin, 2010; Mills et al., 2004). The relationship is intricate 
and involves various levels of cooperation and competition (Kass & Jasin, 2010). The 
choice between HR and NHEJ is determined by many factors including the nature of the 
break and the stage within the cell cycle, indicating the two mechanisms work 
collaboratively towards DSB repair. However, despite the co-operative efforts of HR and 
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NHEJ, there is evidence competition exists between the two pathways (Kass & Jasin, 
2010). It has been shown that mutants with a defective NHEJ repair pathways display 
increased levels of resectioned DNA ends (Lee et al., 1998). Conversely mutants with 
reduced levels of resectioned ends exhibit more NHEJ activity (Yun & Hiom, 2009). It is 
this competitive aspect of the relationship between HR and NHEJ that has driven using 
downregulation of NHEJ proteins to enhance HR and subsequently improve gene 
targeting efficiencies. Past research has been done that both supports and opposes this 
approach. A study done in mouse embryonic stem cells found that despite increases in 
HR frequencies when cells were Ku70, XRCC4, or DNA-PKCS null, no changes in gene 
targeting levels were observed (Pierce et al., 2001). Similar results were established with 
the gene targeting frequencies in Arabidopsis thaliana Ku mutants (Jia et al., 2012). 
However, in studies investigating single-celled eukaryotic Ku70 mutants, increases in 
gene targeting frequencies were seen (Ushimaru et al., 2010; Yamana et al., 2005). These 
findings were also supported with research done using human cells. A 5- to 10-fold 
increase in gene targeting was uncovered in Ku70+/- cells during an attempt to generate 
Ku70 null human somatic cells using the rAAV (Fattah et al., 2008). Further 
investigation revealed this was not specific to the Ku70 loci. Additionally, the effect 
could be mimicked using RNAi and shRNA targeting Ku70. The use of RNAi against 
Ku70 and XRCC4 in human HCT116 cells also revealed higher gene targeting 
frequencies that were associated with a reduction in random integrations (Bertolini et al., 
2009).  Together these lend some credence to the results seen when using anti-Ku 
antibodies.  
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One explanation that has been proposed as an explanation for the inconsistencies seen is 
B-NHEJ. The theory that a backup NHEJ pathway exists gained momentum as DSB 
repair activity emerged that could not be attributed to HR or NHEJ (Iliakis, 2009;  Wu et 
al., 2008). When Ku or DNA-PKCS is incapacitated but still able to bind to DNA, end-
joining activity decreases (Morozov & Wawrousek, 2008; Perrault et al., 2004; Wang et 
al., 2003). However, this is only the case when the other DNA-PK complex components 
are present. Moreover, complete removal of Ku or DNA-PKCS from the system results in 
seemingly normal levels of end joining that upon closer investigation show discernable 
differences from the wild type (Morozov & Wawrousek, 2008; Perrault et al., 2004; 
Wang et al., 2003). This evidence suggests that in the presence of Ku and DNA-PKCS B-
NHEJ activity is inhibited while in the absence of Ku or DNA-PKCS B-NHEJ factors can 
readily gain access to the breaks and proceed with DSB repair (Wang et al., 2003). The 
B-NHEJ mechanism has been found to proceed at a slower rate than C-NHEJ and is 
purportedly mediated by Ligase III, Parp-1, and Histone H1 (Iliakis, 2009; Perrault et al., 
2004; Terzoudi et al., 2008; Wu et al., 2008). Evidence suggests end resectioning is 
involved and that the mechanism routinely makes use of microhomologies (Rass et al., 
2012). Consequently microhomology-mediation has also been implicated in the random 
integration of gene targeting vectors, a contributing factor to the problematic low 
frequency of gene targeting (Iiizumi et al., 2008). As a result the present study also 
proposed to investigate how the down-regulation of B-NHEJ proteins impact the repair 
balance between HR and NHEJ.   
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Parp-1 promotes DNA repair by binding to damaged sites and then recruiting repair 
factors (Bryant et al., 2005).  Parp-1 has been associated with base excision repair (BER), 
single-strand break (SSB), and more recently B-NHEJ repair (Bryant et al., 2005; Iliakis, 
2009; Paddock et al., 2011; Perrault et al., 2004; Terzoudi et al., 2008; Wu et al., 2008). 
Research in mice has shown that the manipulation of Parp-1 levels in the cell can affect 
gene targeting efficiencies (Dominguez-Bendala et al., 2006). In mouse embryonic stem 
cells lacking Parp-1 increases in gene targeting were observed (Dominguez-Bendala et 
al., 2006). The effect was also seen with inhibitors of Parp-1 albeit to a lesser extent 
(Dominguez-Bendala et al., 2006). The use of 3-methoxybenzamide (3-MB), a Parp 
inhibitor, in mouse Ltk- cells contributes to a reduction in random integrations indirectly 
resulting in a gene targeting increase (Waldman & Waldman, 1990). But despite the 
reported successes, a separate study in mice embryonic stem and embryonic fibroblast 
cells using Parp-1 deficient cells found no differences in DSB repair and gene targeting 
efficiencies (Yang et al., 2004).  
 
Many of the studies focus on the downregulation of each candidate DSB repair factor 
individually. But with new evidence bringing to light an increasingly complex picture of 
DSB repair, the co-inhibition of different combinations of factors may be a more 
appropriate approach. A recent study noticed that double NHEJ factor mutants repaired 
DSB less efficiently and were more sensitive to ionizing radiation than either single 
mutant suggesting that the role of each factor may be compensated for by other DSB 
repair factors (Zhuang et al., 2011). Thus the transient downregulation of one factor may 
not be as effective as the downregulation of multiple factor when attempting to shift the 
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repair balance. Furthermore as evidence of a B-NHEJ pathway emerges simultaneously 
targeting both end joining pathways might prove to be necessary for increasing the 
frequency of HR. 
 
Besides targeting multiple proteins, there is also some promise in shifting the focus to 
other less explored repair proteins. The p53 binding protein (53BP1) is a protein that has 
been linked to the NHEJ repair pathway (Nakamura et al., 2006; Stavnezer et al., 2008). 
It is recruited quickly to DNA DSBs and mutants show increased radiosensitivity in the 
G1 cell cycle phase (Nakamura et al., 2006; Stavnezer et al., 2008; Xie et al., 2007). 
Targeting the protein 53BP1 with siRNA in mice embryonic stem (ES) cells increases 
HR while chicken DT40 cells lacking 53BP1 display increased levels of gene targeting 
(Nakamura et al., 2006; Xie et al., 2007). Other proteins worth investigating include 
XRCC4 and LIGIV. In CHO cells XRCC4 mutations show signs of increased HR activity 
(Delacote et al., 2002; Johnson et al., 1999), and in Arabidopsis thaliana, LIGIV mutants 
showed increased gene targeting efficiencies (Tanaka et al., 2010). Additionally, mouse 
ES cells (Arbones et al., 1994; Capecchi, 1989; Hall et al., 2009), chicken DT40 cells 
(Buerstedde & Takeda, 1991; Yamazoe et al., 2004), and the human pre-B cell line 
Nalm-6 (Adachi et al., 2008; Adachi et al., 2006) all have naturally increased gene 
targeting levels relative to comparative cell lines. What distinguishes these from other 
vertebrate cells? And which of these differences contribute to the increased levels of gene 
targeting? Identifying what separates the cell lines with naturally enhanced gene targeting 
efficiencies may also help uncover promising proteins to target for downregulation.    
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4.3 Conclusions 
 
Two dominant DSB repair mechanisms exist – HR and NHEJ. Another mechanism, 
known as B-NHEJ, has been uncovered in recent year and its contributions to DSB repair 
continues to be investigated. Over the last half century the HR DSB repair mechanism 
has been exploited by researchers to genetically alter specific loci in a wide range of 
different organisms. This process termed gene targeting is part of an emerging field that 
has useful applications for both the laboratory and clinical setting (de Semir & Aran, 
2006;  Fattah et al., 2008). In the past it has been used to generate knockouts and in the 
recent decade it has been researched as a promising treatment option for many diseases 
through the pretext of gene therapy (Edelstein et al., 2007; Fattah et al., 2008; Tani et al., 
2011). Thus overcoming the challenges impeding the progression and advancement of 
this field continues to be important. Because the low frequency of HR in higher 
eukaryotic organisms has been linked to low gene targeting efficiencies, manipulation of 
DSB repair proteins has been utilised to shepherd the repair balance towards HR. 
However, an overview of studies targeting NHEJ and B-NHEJ repair proteins for 
downregulation does not reveal a unified picture. As more information about the different 
repair pathways and how they co-exist emerges, the list of potential targets and 
approaches to manipulate those targets expands. The approach of the present study 
attempted to utilize antibodies to transiently downregulate various DNA repair proteins. 
The objectives of this experiment were primarily to manipulate the balance of DNA 
repair within human cells so that it shifts away from NHEJ and towards HR. Successful 
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manipulation of the DSB repair has the potential to advance gene targeting in somatic 
mammalian cells and while the attempts of this particular study were unable to 
successfully achieve this, it should continue to be pursued. 
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